

**CURRICULUM VITA**

**Name:** Robert K. Oldham, M.D.  
**Address:** 1082 E. Caribbean  
Summerland Key, FL. 33042

Cell # 305 906 0364

Email: [rko.1@earthlink.net](mailto:rko.1@earthlink.net)

Office: Lower Keys Cancer Center  
Key West, FL 33040

Tele #: 305 292 5809

Fax #: 305 292 5819

Cancer Therapeutics, Inc (CTI)

[www.cancercellulartherapeutics.com](http://www.cancercellulartherapeutics.com)

[www.droldham.com](http://www.droldham.com)

**Social Security #:** Available on request

**Date/Place of Birth:** 9/16/41; Pocatello, Idaho

**Marital Status:** Married Laura Slocumb Oldham  
5 Sons

**College:** University of Missouri, Columbia, MO  
Chemical Engineering  
Pre-Medical Sciences

**Medical School:** 1968, Medical Degree  
University of Missouri  
Columbia, Missouri

**Graduate Training:** 1970-1971 Immunology  
NIH Graduate Program

**Professional Employment:****Business Synopsis**

<b>2011-Present Director:</b> Lower Keys Cancer Center 5900 College Rd. Key West, FL 33040	<b>Patient Care</b>
<b>2010-2011 Hematology-Oncology</b> Poplar Bluff Regional Medical Center 621 W. Pine Poplar Bluff MO 63901	<b>Patient Care</b>
<b>2008-2010: Director:</b> Hematology-Oncology Associates Southeast Missouri Hospital 1701 Lacey St. Cape Girardeau, MO 63701	<b>Patient Care/Clinical Research</b>
<b>2007-2008: Oncologist Practice Oncology/Hematology</b> New Mexico Cancer Center 4901 Lang Ave. N.E. Albuquerque, NM 87109	<b>Patient Care/Clinical Research</b>
1996 - Present Medical Director and Vice President, Business Dev. CBA Research, Inc. 670 Perimeter Drive Lexington, KY 40517	Senior Management Team Reports to CEO.
1997 - 2005 Member, Board of Directors/Trust Committee Immune Complex Corporation/Apovia 11125 Flintkote Ave. Ste. A-E San Diego, CA 92121	Senior Management Team Reported to CEO.
2001 - 2007 Associate Medical Director Singletary Oncology Center 116 Mimosa Dr. Thomasville, GA 31792	Senior Management Team Reported to CEO.
1991- Present Chairman of the Board and CEO Cancer Cellular Therapeutics, Inc.  <a href="http://www.cancercellulartherapeutics.com">www.cancercellulartherapeutics.com</a>	Raised \$2.7M private capital to start the company in 1991. Annual revenue of \$300,000 in 1996 - 1999.
1992 - 2000 Medical Director Cancer Treatment Associates 100 Covey Drive, Suite 111 Franklin, TN 37067	Raised \$800,000 private capital to start predecessor company. Grew company from 1 to 10 people

1984 - Present	Founder and Director Biological Therapy Institute	Committed more than \$1.5 M personal capital to initiate and develop this non-profit Institute.
1994 - Present	Clinical Professor of Medicine University of Missouri Columbia, Missouri 65212	
2001-2007	Clinical Professor of Medicine Florida State University College of Medicine Tallahassee, FL 32306	
1996 - 1997	Vice President, Medical Affairs HealthLine Management, Inc. St. Louis, MO	Senior Management Team Reported to CEO.
1986 -1996	Chairman of the Board Media America Franklin, TN 37064	Media America published <i>Cope</i> and <i>Coping</i> magazines Founded and produces NCSD

**Professional Employment (Continued)****Business Synopsis:**

1984 - 1990	Founder, Scientific Director and Chairman of the Board Biotherapeutics, Inc. (NASDAQ Company)	Raised \$3.0 M private capital to initiate this company then raised \$37 M public capital taking Biotherapeutics to the American Stock Exchange
1984 - 1986	Founder and Consultant Biomedical Research Center University of British Columbia Vancouver, British Columbia V6T 2B5	Developed business relationship with Wellcome Pharmaceuticals to fund and initiate this research center.
1980 - 1984	Founding Director Biological Response Modifiers Program Associate Director Division of Cancer Treatment National Cancer Institute Frederick, Maryland 21701	Founded this NCI program with an annual budget of \$14.0 M and grew the program from one person to 200 people with an annual budget in excess of \$20.0 M.
1975 - 1980	Founder and Director, Division of Oncology Associate Professor of Medicine Associate Director; Cancer Center Vanderbilt University Medical Center Nashville, TN 37232	Founded this program with \$100,000 of Vanderbilt investment to a program growing from one person to 35 individuals and an annual budget in excess of \$3.0 M by 1980.
1974 - 1975	Senior Investigator Laboratory of Immunodiagnosis National Cancer Institute Bethesda, Maryland 20205	
1973 - 1974	Senior Investigator Cellular and Tumor Immunology Section Laboratory of Cell Biology National Cancer Institute Bethesda, Maryland 20205	

**Professional Employment Cont:**

- 1972 - 1973      Research Associate with  
Professor G. Mathe  
ICIG - Hospital Paul Brousse  
Villejuif, France
- 1971 - 1972      Clinical Associate-Oncology Fellowship  
Cellular and Tumor Immunology Section  
Laboratory of Cell Biology  
National Cancer Institute  
Bethesda, Maryland 20205
- 1970 - 1971      Clinical Associate-Oncology Fellowship  
Radiation Branch  
National Cancer Institute  
Bethesda, Maryland 20205
- 1968 - 1970      Intern and Resident  
Internal Medicine  
Vanderbilt University Hospital  
Nashville, Tennessee 37205

**Clinical Group Appointments:**

1976 - 1980           Principal Investigator - Vanderbilt  
                          Southeastern Oncology Study Group (NCI)

1978 - 1980           Principal Investigator - Vanderbilt  
                          Lung Cancer Study Group (NCI)

1986 - 1990           Founder and Group Chairman -  
                          National Biotherapy Study Group

1986- 2001           Principal Investigator - Biological Therapy  
                          Institute - National Biotherapy Study Group  
                          ( Cancer Biotherapy Research Group)

**Fellowship Experience:**

1970 - 1972           Medical Oncology Fellowship, National Cancer Institute -  
                          Bethesda, Maryland

1967                   PHS Cancer Clinical Fellowship, Lemuel Shattuck  
                          Hospital-Jamaica Plain - Boston, Massachusetts

1967                   PHS Cancer Clinical Fellowship, Ellis Fischel Cancer  
                          Hospital - Columbia, Missouri

1965                   PHS Student Research Fellowship, University of  
                          Missouri Medical School - Columbia, Missouri

**Honors, Awards and Societies:**

1967           Alpha Omega Alpha

1970           Diplomat, National Board of Medical Examiners

1975           Diplomat, American Board of Internal Medicine

1975           Diplomat, Medical Oncology, American Board of  
                  Internal Medicine

1976           American Association of Immunologists

1976           International Society for Experimental Hematology

1977           Southern Medical Association

1977           American Federation for Clinical Research

1977           American Society for Clinical Oncology

1978           American College of Physicians, Fellow

1979           Southern Society for Clinical Investigation

1982           American Osler Society

1984           Society for Biological Therapy, Founder  
                  President - May 1984 to November 1986

1984           Reticuloendothelial Society

1986	National Biotherapy Study Group, Founder Group Chairman - 1986 to 1990
1990	Association of Community Cancer Centers
1994	International Cytokine Society
1994	The American Association of Bioethics

**Licensure:**

Tennessee, Missouri and Georgia, Illinois and New Mexico (active)  
Maryland (inactive)

**Consultant:**

**1999-2004      Consultant Cell Genesys and Xocyte Therapies**

1999 - 2000	Senior Consultant, American Red Cross
1999 - 2002	Maxim Pharmaceuticals San Diego, California 92122
1989 – 2001	Nycomed-Amersham Buckinghamshire, England
1984 - 1986	Wellcome Biotechnology Ltd. Kent, England
1991 - 1996	Cancer Treatment Centers of America Zion, Illinois
1994 - 1996	Applied Immune Sciences (GenCell) Santa Clara, California 95054
1996- 1999	Jenner Biotherapies San Ramone, CA 95054

**Editorial Boards:**

1992 - Present	Cancer Biotherapy, Founder, (now Cancer Biotherapy & Radio-pharmaceuticals- Co-Editor-in-Chief)
1990 - 1999	In Vivo, Editorial Board Natural Immunity and Cell Growth Regulation, Editorial Board
1988 - 1992	Molecular Biotherapy, Founder and Editor-in-Chief
1982 - 1989	Journal of Biological Response Modifiers (now Journal of Immunotherapy) Founder and Editor-in-Chief
1982 - 1985	Cancer Immunology and Immunotherapy, Editorial Board

**Major Research Interests:**

Cancer Biotherapy  
Cellular Therapy of Cancer  
Biologicals and Biological Response Modifiers  
Investigative Trials in Clinical Oncology  
Monoclonal Antibodies & Immunoconjugates in Cancer Treatment  
In Vitro Assays in Tumor Immunology  
Privatization of Cancer Research  
Cost-effective Clinical Care



**Major Accomplishments** (Curriculum Vitae # - over 400 published papers)

Discovery of Natural Killer Cells

(#8, 9, 27, 28, 31, 46, 47, 56, 90, 92, 121, 157 323)

Development of improved therapy for small cell lung cancer

(#66, 69, 78, 80, 85, 95, 103, 105, 108, 124, 177)

Development of improved therapy for ovarian cancer

(#99, 102, 125)

Development of improved methods in detecting and treating extragonadal germ cell tumors and other poorly differentiated tumors

(#22, 87, 93, 122, 123, 227, 228; 5-Book)

Use of cryopreserved cells for standardized immunological testing

(#37, 38, 40, 41, 45, 49, 52, 120)

Cancer Biotherapy: first to use the term to describe a fourth modality of cancer treatment

(#109, 114, 119, 128, 129, 134, 137, 139, 141, 146, 151, 153, 154, 161, 169, 173, 174, 175, 176, 179, 181, 183, 184, 188, 193, 197, 204, 206, 212, 225, 240, 249, 250, 184, 188, 193, 197, 204, 206, 212, 225, 240, 249, 250, 252, 260, 261, 262, 264, 265, 266, 267, 301, 302, 314, 319, 322, 324, 325; 332, 333, 338, 339, 340, 343, 344, 346, 349, 356, 357, 358, 360, 361, 362, 363, 10 Books)

Monoclonal antibodies and immunoconjugates in cancer treatment: Did groundbreaking experiments with toxin, drug and isotope conjugates

(#125, 126, 140, 143, 144, 145, 150, 152, 155, 156, 159, 160, 165, 180, 181, 182, 185, 187, 195, 196, 198, 199, 206, 218, 223, 224, 235, 238, 241, 244, 246, 247, 248, 251, 253, 254, 263, 278, 279, 285, 286, 287, 288, 291, 306, 307, 310, 311, 318, 325, 327, 342, 347)

Cytokine and Cellular Therapy: Conducted some of initial clinical experiments with IL-2 in LAK and T cell therapy

(#249, 255, 259, 281, 290, 294, 295, 298, 301, 302, 309, 311, 314, 322, 324, 332, 333, 349, 356, 357, 358, 361, 362)

Individualized Cancer Treatment: Conducted specific laboratory and clinical experiments demonstrating that each cancer in each patient has unique characteristics which may require unique, individualized treatment

(#267, 279, 285- 288, 291, 306, 307, 310, 318, 325, 327, 342, 347)

Privatization of Cancer Research: Brought attention to clinical research opportunities in the private sector. Published widely on problems of access to new technologies and the funding of clinical research.

(#134, 205, 206, 207, 231, 236, 245, 256, 257, 268, 269, 282, 284, 289, 293, 308, 312, 316, 317, 319, 321, 325, 326, 330, 331, 334, 335, 350, 352, 353, 354, 355, 358, 359, 364, 11-Books)

## **Publications**

Over 400 papers published in the medical/scientific literature

Thousands of abstracts, posters and presentations at various meetings on cancer research and treatment

Editor of Principles of Cancer Biotherapy, the first comprehensive textbook on the fourth modality of cancer treatment (Now in Fifth Edition, 2009 - Springer Publishers).

Editor of Principles of Cancer Biotherapy:  
First Edition, 1987, Raven Press  
Second Edition, 1991, Marcel Dekker  
Third Edition, 1998, Kluwer Academic Publishers  
Fourth Edition, 2004, Kluwer Academic Publishers  
Fifth Edition, 2009, Springer-Verlag Publishers

Founding Editor of Cancer Biotherapy, (now Cancer Biotherapy & Radiopharmaceuticals), Molecular Biotherapy and the Journal of Biological Response Modifiers (now Journal of Immunotherapy).

Author or editor of fifteen books on cancer research and treatment

Author of two published novels

## **BIBLIOGRAPHY**

### **Published Papers**

1. Oldham, R.K.: Terminal cancer - A patient oriented approach. *J. Tenn. Med. Assoc.*, 63:206, 1970.
2. Oldham, R.K.: Aseptic meningitis following the intrathecal injection of RISA. *Radiology*, 97:317, 1970.
3. Oldham, R.K.: Eosinophilic Granuloma. *South. Med. J.*, 64:978, 1971.
4. Oldham, R.K. and Pomeroy, T.C.: Vincristine induced inappropriate ADH syndrome. *South. Med. J.*, 65:1010-1012, 1972.
5. Oldham, R.K. and Pomeroy, T.C.: Treatment of Ewing's sarcoma with Adriamycin. *Cancer Chemotherapy Reports*, 56:635-639, 1972.
6. Oldham, R.K. and Pomeroy, T.C.: Extramedullary plasmacytomas following successful radiotherapy of Hodgkin's disease: Clinical and immunological aspects. *American J. Med.*, 54:761-767, 1973.
7. Oldham, R.K., Larson, S.M., and Givelber, H.M., Chretien, P.B., and Johnson, R.E.: A preliminary study of <sup>51</sup>Cr-labeled platelets for evaluation of splenic sequestration in chronic lymphocytic leukemia. *J. Nuclear Med.*, 37:219-222, 1973.
8. Oldham, R.K., Siwarski, D., McCoy, J.L., Plata, E.J., and Herberman, R.B.: Evaluation of a cell-mediated cytotoxicity assay utilizing <sup>125</sup>Iododeoxyuridine labeled tissue culture targets. *Nat. Cancer Inst. Monogr.*, 37:49-58, 1973.
9. Oldham, R.K., Herberman, R.B.: Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigen utilizing <sup>125</sup>Iododeoxyuridine labeled target cells. *J. Immunol.*, 111:1862-1971, 1973.
10. Lemevel, B.P., Oldham, R.K., Wells, S.A., and Herberman, R.B.: An evaluation of <sup>125</sup>Iododeoxyuridine as a cellular label for in vitro assays - Kinetics of incorporation and toxicity. *J. Nat. Cancer Inst.*, 51:1511-1558, 1973.
11. Oldham, R.K. and Simmler, M.C.: The use of cryopreserved lymphocytes and lymphoblasts in <sup>51</sup>Cr lymphocyte cytotoxicity. In Weiner, R.S., Oldham, R.K., and Schwarzenberg, L. (Eds.): *The Cryopreservation of Normal and Neoplastic Cells*, Inserm, Institute National de la Sante et de la Recherche Medicale. Paris, pp. 161-169, 1973.
12. Oldham, R.K. and Simmler, M.C.: Possible role of lymphocyte cytotoxicity in bone marrow grafting. *Trans. Proceed.*, 6:417, 1974.
13. Jasmin, C., Bricout, F., Huraux, J.M., Weiner, R., Oldham, R.K., and Mathe, G.: A study of viral infections in patients treated with a combination of 6-mercaptopurine-methotrexate: Preliminary results. In Mathe, G., and Oldham, R.K. (Eds.): *Recent Results in Cancer Research: Complications of Cancer Chemotherapy*, Vol. 49. New York, Springer-Verlag, pp. 29-33, 1974.
14. Mathe, G. and Oldham, R.K.: Introduction. In Mathe, G. and Oldham, R.K. (Eds.): *Complications of Cancer Chemotherapy*. New York, Springer-Verlag, pp. 1-2, 1974.
15. Beard, J., Weiner, R.S., Oldham, R.K., and Mathe, G.: Immune responsiveness in acute lymphocytic leukemia patients under chemotherapy and immunotherapy: A preliminary report. In Mathe, G. and Oldham, R.K. (Eds.): *Recent Results in Cancer Research: Complications of Cancer Chemotherapy*. New York, Springer-Verlag, pp. 56-60, 1974.
16. Belpomme, D., Carde, P., Oldham, R.K., Mathe, G., Jacquillat, N., Chelloul, N., Weil, M., Auclerc, C., Weisgerber, G., Tanzer, T., and Bernard, J.: Malignancies possibly secondary to anticancer therapy. In Mathe, G., and Oldham, R.K. (Eds.): *Recent Results in Cancer Research: Complications of Cancer Chemotherapy*. New York, Springer-Verlag, pp. 115-123, 1974.

17. Mathe, G., Schwarzenberg, L., Pouillart, P., Weiner, R., Oldham, R.K., Jasmin, C., Hayat, M., Schneider, M., Amiel, J.L., Ceoara, B., and Steresco-Musset, M.: Essai de Traitement de divers hematosarcomas: par le 4-demethyl-epipodophyllotoxine beta.D. thenylidene glucoside(VM 26 ou EPT). *La Nouvelle Presse Med.*, 3:337-451, 1974.
18. Mathe, G., Schwarzenberg, L., Pouillart, P., Wiener, R., Oldham, R.K., Jasmin, C., Hayat, M., Schneider, M., Amiel, J.L., Ceoara, B., and Steresco-Musset, M.: Leucemies aigues et hematosarcomas divers: Essai de traitement par un second derive de la podophyllotoxine (le 4-Demethylepipodophyllotoxine Beta.D. ethylidene glucoside VP16-213 ou EPE). *La Nouvelle Presse Med.*, 3:521-524, 1974.
19. Mathe, G., Schwarzenberg, L., Pouillart, P., Oldham, R.K., Wiener, R., Jasmine, C., Hayat, M., Schneider, M., Amiel, J.L., de Vassal, F.: Two epipodophyllotoxin derivatives, VP 26 and VP16-213 in the treatment of leukemias and hematosarcomas. *In* Bucalossi, P., Veronesi, U., Bonadonna, G., and Emanuelli, H. (Eds.): *I Linfomi Maligni*. Milano, Casa Editrice Ambrosiana, pp. 303-309, 1974.
20. Mathe, G., Schwarzenberg, L., and Oldham, R.K.: le controle et le traitement de l'insuffisance medullaire qui peut compliquer les lymphomes et/ou leurs traitements. *In* Bucalossi, P., Veronesi, U., Bonadonna, G., and Emanuelle, I. (Eds.): *I Linfomi Malogni*. Milano, Casa Editrice Ambrosiana, pp. 359-365, 1974.
21. Herberman, R.B., Char, D., Oldham, R.K., Levine, P., Leventhal, B.G., and McCoy, J.L.: Cell-mediated immunity in human acute leukemia. *In* Ito, Y., and Dutcher, R.M. (Eds.): *Comparative Leukemia Research*. University of Tokyo/Karger, pp. 585-592, 1974.
22. Mathe, G., Schwarzenberg, L., Pouillart, P., Oldham, R.K., Weiner, R., Kasom, C., Hayat, M., Sachneider, M., Amiel, J.L., and de Vassa, F.: Two epipodophyllotoxin derivatives, VP 26 and VPI6-213, in the treatment of leukemias and hematosarcomas. *Cancer*. 34:985-992, 1974.
23. Herberman, R.B., Hollinshead, A., Char, D., Oldham, R.K., McCoy, J.L., and Cohen, M.: *In vivo* and *in vitro* studies of cell-mediated immune response to antigens associated with malignant melanoma. *In* International Symposium on Immuno-logical Reactions to Melanoma Antigens. Behring Institute Research Communications, Behringwerke AG. West Germany, Marburg Publisher, No. 56, pp. 131-138, 1974.
24. Herberman, R.B., Char, D.H., Oldham, R.K., and Leventhal, B.G.: The prognostic value of studies of specific cell-mediated immunity in acute leukemia. *In* T.M. Fleidner and S. Perry (Eds.): *Advances in the Biosciences 14. Workshop on Prognostic Factors in Human Acute Leukemia*. Branschweig, West Germany, Friedr. Viewegh and Sohn, pp. 431-440, 1975.
25. Pouillart, P., Weiner, R., Scharzenberg, L., Missel, J.L., Oldham, R.K., Amiel, J.L., Mathe, G.: Combination chemotherapy based on a model of cell recruitment by partial synchronization. *Med. and Ped. Oncology.*, 1:123-134, 1975.
26. McCoy, J.L., Jerome, L.F., Dean, J.H., Perlin, E., Oldham, R.K. Char, D.H., Cohen, M.H., Felix, E.L., and Herberman, R.B.: In- hibition of leukocyte migration by tumor-associated antigens in soluble extract of human malignant melanoma. *J. Natl. Cancer Inst.*, 55:19-23, 1975.
27. Herberman, R.B. and Oldham, R.K.: Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. *J. Natl. Cancer Inst.*, 55:749-753, 1975.
28. Oldham, R.K., Djeu, J.Y., Cannon, G.B., Siwarski, D., Herberman, R.E.: Cellular microcytotoxicity in human tumor systems: Analysis of results. *J. Natl. Cancer Inst.*, 55:1305-1318, 1975.
29. Catalona, W.L., Oldham, R.K., Djeu, J.Y., Herberman, R.B., and Cannon, G.B.: Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24. *Surgical Forum*, 26:122-124, 1975.
30. Law, I.P., Koch, F.J., Cannon, G.B., Herberman, R.B., and Oldham, R.K.: Acute myelomonocytic leukemia associated with paraproteinemia. *Cancer*, 37:1358-1364, 1976.

31. Oldham, R.K., Weiner, R.S., Mathe, G., Breard, J., Simmler, M.C., Carde, P., and Herberman, R.B.: Cell-mediated immune responsiveness of patients with acute lymphocytic leukemia in remission. *Int. J. Cancer*, 17:326-337, 1976.
32. McCoy, J.L., Dean, J.H., Cannon, G.B., Maurer, B.A., Oldham, R.K., and Herberman, R.B.: Detection of cell-mediated immunity against tumor associated antigens of human breast carcinoma by migration inhibition and lymphocyte stimulation assays. *In* J. Wybran and M. Staquet (Eds.): *Clinical Tumor Immunology*. Oxford, England, Pergamon Press, pp. 77-86, 1976.
33. Campbell, D.A., Oldham, R.K., Ortaldo, J.R., Nunn, M.E., Holden, H.T., Herberman, R.B.: Effect of X-irradiation on tumor associated antigens. *In*: Neibings, H.E. (Eds.): *Detection and Presentation of Cancer*. New York, Marcel Dekker, Inc., pp.447- 465, 1978.
34. Herberman, R.B., Campbell, D.A., Jr., Oldham, R.K., Bonnard, G.D., Ting, C.C., Holden, H.T., Glaser, M., Djeu, J., and Oehler, R.: Immunogenicity of tumor antigens. *Ann. N.Y. Acad. of Sci.*, 276:26-39, 1976.
35. Oldham, R.K. and Herberman, R.B.: Determination of cell-mediated cytotoxicity by the 125Iododeoxyuridine microcytotoxicity assays. Bloom, B.R., and David, J.R. (Eds.):*In: In Vitro* Immunity. Academic Press, New York, pp. 461-470, 1976.
36. Herberman, R.B., Oldham, R.K., Connor, R.J.: Statistical analysis and selection of baseline control in cytotoxicity assays. Bloom, B.R. and David, J.R. (Eds.):*In: In Vitro* Methods in Cell Mediated and Tumor Immunity. Academic Press, New York, 481-488, 1976.
37. Holden, H.T., Oldham, R.K., Ortaldo, J.R., Herberman, R.B.: Cryopreservation of the functional reactivity of normal and immune leukocytes and of tumor cells. Bloom, B.R. and David, J.R. (Eds.):*In: In Vitro* Methods in Cell Mediated and Tumor Immunity. Academic Press, New York, pp. 723-729, 1976.
38. Ortaldo, J.R., Oldham, R.K., Holden, H.T., Herberman, R.B.: Immune response to Gross virus induced lymphoma: Cryopreservation of functional activity of rat lymphocytes and tumor cells. *Cell. Immunol.*, 25:60-73, 1976.
39. McCoy, J.L., Jerome, L.F., Anderson, C., Cannon, G.B., Alford, T.C., Connor, R.J., Oldham, R.K., and Herberman, R.B.: Leukocyte migration inhibition by soluble extracts of MCF-7 tissue culture cell line derived from breast carcinoma. *J. Natl. Cancer Inst.* 57:1045-1049, 1976.
40. Oldham, R.K., Dean, J., Cannon, G.B., Graw, R., Dunston, G., Appleaum, F., McCoy, J., Djeu, J. and Herberman, R.B.: Cryopreservation of human lymphocyte function as measured by *in vitro* assays. *Int. J. Cancer*, 18:145-155, 1976.
41. Oldham, R.K., Weese, J.L., Herberman, R.B., Perlin, E., Mills, M., Heim, W., Blom, J., Green, D., Reid, J., Bellinger, S., Law, I., McCoy, J.L., Dean, J.H., Cannon, G.B., Djeu, J.: Immunological monitoring and immunotherapy in carcinoma of the lung. *Int. J. Cancer*, 18:739-749, 1976.
42. Campbell, D.A., Manders, E.K., Oehler, J.R., Bonnard, G.D., Oldham, R.K., Herberman, R.B.: Inhibition of *in vitro* lymphoproliferative response by *in vivo* passaged rat 13762 mammary adenocarcinoma cells, I: Characteristics of inhibition and evidence for an infectious agent. *Cell. Immunol.*, 33:363- 377, 1977.
43. Campbell, D.A., Jr., Staal, S.P., Manders, E.K., Bonnard, G.D., Oldham, R.K., Salzman, L.A., Herberman, R.B.: Inhibition of *in vitro* lymphoproliferative responses by *in vivo* passaged rat 13762 mammary adenocarcinoma cells. II: Evidence that Kilham rat virus is responsible for the inhibitory effect. *Cell. Immunol.* 33:378-391, 1977.
44. Djeu, J., Payne, S., Alford, C., Heim, W., Pomeroy, T., Cohen, M., Oldham, R.K., Herberman, R.B.: Detection of decreased proportion of lymphocytes forming rosettes with sheep erythrocytes at 29 C in the blood of cancer patients: Analysis of factors affecting the assay. *Clinical Immunol. and Immunopath .*, 8:405-412, 1977.

45. Holden, H.T., Oldham, R.K., Ortado, J.R., and Herberman, R.B.: Standardization of the <sup>51</sup>Cr release cell-mediated cytotoxicity assay: Cryopreservation of mouse effector and target cells. *J. Natl. Cancer Inst.* 58:611-622, 1977.
46. Oldham, R.K., Ortaldo, J., Herberman, R.B.: Natural cytotoxic reactivity of rat lymphocytes as measured by the (125I) iododeoxyuridine and tritiated proline microcytotoxicity assays in the Gross virus induced lymphoma system. *Cancer Res.* 32:4457-4463, 1977.
47. Ortaldo, J.R., Oldham, R.K., Cannon, G.B., and Herberman, R.B.: Specificity of "natural cytotoxicity" on normal human lymphocytes against a myeloid leukemia cell line, K562. *J. Natl. Cancer Inst.* 59:77-82, 1977.
48. Weese, J.L., Oldham, R.K., Tormey, D.C., Barlock, A.L., Morales, A., Cohen, M.H., Alford, T.C., Shorb, P.E., Tsangaris, N.T., West, W.H., Cannon, G.B., Dean, J.H., Djeu, J., and McCoy, J.L.: Immunologic monitoring in carcinoma of the breast. *Surg., Gynec. Obst.*, 145:209-218, 1977.
49. Dean, J.H., Connors, R., Herberman, R.B., Silva, J., McCoy, J.L., and Oldham, R.K.: The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens. *Int. J. Cancer*, 20:359-370, 1977.
50. Law, I.P., Herberman, R.B., Oldham, R.K., Bouzoukis, J., Hanson, S.M., Rhode, M.C.: Familial occurrence of colon and uterine carcinoma and of lymphoproliferative malignancies: I. Clinical description. *Cancer*, 39:1224-1228, 1977.
51. Law, I.P., Hollinshead, A.C., Whang-Peng, J., Dean, J.H., Oldham, R.K., Herberman, R.B., Rhode, M.C.: Familial occurrence of colon and uterine carcinoma and of lymphoproliferative malignancies. II. Chromosomal and immunologic abnormalities. *Cancer*, 39:1229-1236, 1977.
52. Oldham, R.K., Ortaldo, J.R., Holden, H.T., Herberman, R.B.: Cytotoxicity inhibition assay: Cryopreservation and standardization. *J. Natl. Cancer Inst.* 59:1321-1323, 1977.
53. Greco, F.A., Oldham, R.K.: Adriamycin irradiation reactions. *Annals of Internal Medicine*, 86(5):655-656, 1977.
54. Catalona, W.J., Oldham, R.K., Herberman, R.B., Djeu, J.Y., Cannon, G.B.: Lack of specificity of lymphocyte-mediated cytotoxicity against the bladder cancer cell line, T24. *J. of Urol.*, 118:254-257, 1977.
55. McCoy, J.L., Jerome, L.J., Cannon, G.B., Pomeroy, T.C., Connor, R.J., Oldham, R.K., Weese, J.L., and Herberman, R.B.: Leukocyte migration inhibition in patients with Ewing's sarcoma by 3-M potassium chloride extracts of fresh and tissue-culture Ewing's sarcomas. *J. Natl. Cancer Inst.*, 59:1119-1125, 1977.
56. Oldham, R.K., Ortaldo, J.R., Holden, H.T., Herberman, R.B.: A direct comparison of three isotopic release microtoxicity assays as measures of cell-mediated immunity to a Gross virus-induced lymphoma in rats. *J. Natl. Cancer Inst.*, 58:1061-1067, 1977.
57. Oldham, R.K.: Adjuvant chemo-immunotherapy of cancer. *J. of Tenn. Med. Assoc.*, 70:87-92, 1977.
58. Dean, J.H., McCoy, J.L., Cannon, G.B., Leonard, C.M., Perlin, E., Kreutner, A., Oldham, R.K., Herberman, R.B.: Cell mediated immune response of breast cancer patients to autologous tumor associated antigens. *J. Natl. Cancer Inst.*, 58:549-555, 1977.
59. Perlin, E., Weese, J.L., Heim, W., Reid, J., Oldham, R.K., Mills, M., Miller, C., Blom, H., Green, D., Bellinger, S., Jr., Law, I., Cannon, G.B., and Herberman, R.B.: Immunotherapy of carcinoma of the lung with BCG and allogeneic tumor cells. In Crispen, R.G. (Ed.): *Neoplasm Immunity: Solid Tumor Therapy*. Chicago, Illinois, Franklin Institute Press, pp. 9-12, 1977.
60. Richardson, R.L., Oldham, R.K., Pomeroy, T.C., Weese, J.L., McCoy, J.L., Cannon, G.O., Dean, J.H., and Herberman, R.B.: Immunological monitoring in Ewing's sarcoma. *Cancer Immunol. Immunother.* 4:87-94, 1978.

61. Dean, J.H., McCoy, J.D., Cannon, G.B., Weese, J.L., Oldham, R.K., and Herberman, R.T.B.: Lymphocyte proliferative responses of patients with carcinoma of breast or lung to mitogens, alloantigens, and tumor-associated antigens. In: Neslurghs, H.E. (Ed.): Detection and Prevention of Cancer. New York, Marcel Dekker, pp. 549-568, 1978.
62. Oldham, R.K. and Herberman, R.B.: Delayed hypersensitivity skin tests. In Herberman, R.B. and McIntire, R.(Eds.): Immunodiagnosis of Cancer. New York, Marcel Dekker, Inc., Vol. 2(7):940-963, 1978.
63. Weese, J.L., Herberman, R.B., Hollinshead, A.C., Cannon, G.B., Keels, M., Kibrite, A., Morales, A., Char, D.H., Oldham, R.K.: Specificity of delayed hypersensitivity reactions to extracts of human tumor cells. J. Natl. Cancer Inst., 60:255-263, 1978.
64. Greco, F.A., Richardson, R.L., Schulman, S.F., Oldham, R.K.: Combination of Constant-Infusion 5-Fluorouracil, Methyl-CCNU, Mitomycin C, and Vincristine in advanced colorectal carcinoma. Cancer Treat. Rep., 62:1407-1408, 1978.
65. Greco, F.A., Oldham, R.K., Richardson, R.L., Murphy, D.L.: Immunologic function in man receiving lithium carbonate. Biomedicine, 29:223-225, 1978.
66. Greco, F.A., Einhorn, L.H., Richardson, R.L., Oldham, R.K.: Small cell lung cancer: Progress and perspective. Semin. Oncol., 5(3):323-335, 1978.
67. Richardson, R.L., Greco, F.A., Oldham, R.K., Liddle, G.W.: Tumor products and potential markers in small cell lung cancer. Semin. Oncol., 5(3):253-262, 1978.
68. Forbes, J.T., Greco, F.A., Oldham, R.K.: Immunologic aspects of small cell carcinoma. Semin. Oncol., 5(3):263-272, 1978.
69. Greco, F.A., Richardson, R.L., Schulman, S.F., Stroup, S. Oldham, R.K.: Treatment of oat cell carcinoma of the lung : complete remissions, acceptable complications, and improved survival. British Med. J., 2:10-11, 1978.
70. Greco, F.A., Fer, M.F., Richardson, R.L., Hande, K.R., Van Boxtel, C.J., Oldham, R.K.: High dose methotrexate with citrovorum factor rescue in non-small cell lung cancer. Cancer Chemother. Pharmacol, 1:255-257, 1978.
71. Oldham, R.K.: High affinity T cell rosettes. In Herberman, R.B. (Ed.): Compendium of Assays for Immunodiagnosis of Human Cancer. North Holland New York, Elsevier, Vol. 1:165-169, 1979.
72. Beatty, P.G., Oates, J.A., Oldham, R.K.: Renal cell carcinoma metastatic to a pheochromocytoma. J. of Urology, 122:544-545, 1979.
73. Presant, C.A., Bartolucci, A.A., Ungaro, P., Oldham, R.K.: Piperazinedinone: A phase II trial in malignant melanoma, Cancer Treat. Rep. 63:1367-1370, 1979.
74. Beatty, P.G., Greco, F.A., Oldham, R.K.: Oncology grand rounds - bone marrow transplantation. J. Tenn. Med. Assoc., 72:361-366, 1979.
75. Oldham, R.K.: Agarose leukocyte migration inhibition (LMI). In Compendium of Assays for immunodiagnosis of Human Cancer. North Holland, New York, Elsevier Vol., 1:449-455, 1979.
76. Eagan, R., Feld, R., Gail, M., Hill, L., Holmes, C., Lukeman, J., McGuire, W., Mountain, C., Oldham, R.K., Pearson, G., and Wright, P.: The National Adjuvant Trials in resectable non- small cell bronchogenic carcinoma. In Jones, S.E., Salmon, S.E. (Eds.): Adjuvant Therapy of Cancer II, New York, Grune, & Stratton, 1979.
77. Fer, M.F., Oldham, R.K., Prager, R.L. and Greco, F.A.: Resectable lung cancer. J. Tenn. Med. Assoc. 72:594-598, 1979.

78. Greco, F.A., Richardson, R.L., Snell, J.D., Stroup, S.L., Oldham, R.K.: Small cell lung carcinoma: complete clinical, radiographic, and bronchoscopic remission and improved survival. *Am. J. Med.* 66:625-630, 1979.
79. Herberman, R.B., Weese, J.L., Bonnard, G.D., Perlin, E., Heim, W., Millar, C., Reid, J., and Oldham, R.K.: Prospects for immunotherapy of lung cancer with specific immunoadjuvants. *In* Muggia, F. and Rosewoweig, M. (Eds.): *Lung Cancer: Progress in Therapeutic Research*. New York, Raven Press, pp. 521-529, 1979.
80. Greco, F.A., Oldham, R.K.: Small cell lung cancer. *New Engl. J. Med.* 301:355-357, 1979.
81. Perlin, E., Oldham, R., Weese, J., Heim, W., Reid, J., Mills, M., Miller, C., Blom, J., Green, D., Bellinger, S, Jr., Cannon, G, Law, I., Connor, R., and Herberman, R.B.: Immunotherapy of carcinoma of the lung with intradermal BCG and allogeneic tumor cells. *Int. J. of Radiat. Oncol., Biol. and Phys.*, 6:1033-1039, 1980.
82. Greco, F.A., and Oldham, R.K.: Treatment of superior vena cava syndrome from small cell lung cancer. *N. Engl. J. Med.*, 302:61, 1980.
83. Oldham, R.K., and Greco, F.A.: Small cell carcinoma of the bronchus. *Lancet*, 1:478, 1980.
84. Forbes, J.T., Greco, F.A., Oldham, R.K.: Natural cell-mediated cytotoxicity in human tumor patients. *In* Herberman, R.B. (Ed.): *Natural Cell-Mediated Immunity against Tumors*. New York, Academic Press, 1031-1046, 1980.
85. Oldham, R.K., and Greco, F.A.: Small cell lung cancer: a curable disease. *Cancer Chemother. Pharmacol*, 4:173-177, 1980.
86. Lojek, M.A., Fer, M.F., Oldham, R.K., Greco, F.A., Roger, L.W.: Cushing's syndrome with metastatic nonkartinizing carcinoma of the cervix. Report of a case and literature review. *Am. J. Med.*, 69:140-144, 1980.
87. Williams, S.D., Einhorn, L.H., Greco, F.A., Oldham, R.K., Fletcher, R.: VP-16-213. Salvage therapy for refractory germinal neoplasms. *Cancer*, 46:2154-2158, 1980.
88. Reid, J.W., Perlin, E., Oldham, R.K., Weese, J.L., Heim, W., Mills, M., Millar, C., Blom, J., Green, D., Ballinger, S., Cannon, G.B., Law, I., Connor, R., Herberman, R.B.: Immunotherapy of carcinoma of the lung with intradermal BCG and allogeneic tumor cells: a clinical trial. *In* Terry, W. (Ed.): *Immunotherapy of Cancer: Present Status of Trials in man*. New York, Raven Press, 1980.
89. Knost, J.A., Reynolds, V., Greco, F.A., Oldham, R.K.: Adjuvant chemoimmunotherapy stage I/II malignant melanoma. *J.Surg. Oncol*, 19:165-170, 1982.
90. Forbes, J.T., Niblack, G.D., Fuchs, R., Richie, R.E., Johnson, H.K., and Oldham, R.K.: Human natural cell-mediated cytotoxicity I. Levels in peripheral blood, cord blood, and thoracic duct lymphocytes. *Cancer Immuno. and Immunother*, 11:139-146, 1981.
91. Forbes, J.T., Greco, F.A., Oldham, R.K.: Human natural cell-mediated cytotoxicity II. Levels in neoplastic disease. *Cancer Immunol. and Immunother*, 11:139-146, 1981.
92. Forbes, J.T., Oldham, R.K.: Kinetic analysis of specificity in human natural cell-mediated cytotoxicity. *In* Herberman, R.B. (Ed.): *Natural Cell-Mediated Immunity Against Tumors*. New York, Academic Press, 819-834, 1980.
93. Richardson, R., Schoumacher, R., Oldham, R.K., Fer, M., Hande, R., Forbes, J.T., and Greco, F.A. The unrecognized extragonadal germ cell cancer syndrome. *Ann. Int. Med.*, 94:181-186, 1981.
94. Greco, F.A., Hande, R.K., Richardson, R.L., and Oldham, R.K.: High dose methotrexate in combination chemotherapy in small cell lung cancer. *In* Mathe and Muggia, (Eds.): *Recent Results in Cancer Research*. New York, Plenum Press, 74:50-55, 1980.



95. Greco, F.A., Oldham, R.K.,: Combined therapy in limited stage small cell bronchial carcinoma. In Whitehouse, M. and Williams, C. (Eds.): Recent Advances in Clinical Oncology. London, England, Churchill Livingstone, 325-339, 1982.
96. Gail, M.H., Oldham, R.K., Holmes, E.C., Wright, P.W., McGuire, W.B., Mountain, C.F., Lukeman, J.M., Feld, R., Hill, L.D., Eagan, R.T., Pearson, F.G., and Lung Cancer Study Group: Early of intrathoracic BCG therapy in patients with non-stage I lung cancer: data from a randomized double-blind controlled trial by the lung cancer study group. *Cancer Immunol. and Immunother.* 10:129-137, 1981.
97. Knost, J.A., Oldham, R.K., Hande, K.R., Rhamy, R.K., Greco, F.A.:The combination of vinblastine and bleomycin in metastatic renal cell carcinoma. *Cancer Treat. Rep.*, 65:349-350, 1981.
98. Knost, J.A., Greco, F.A., Hande, K.R., Richardson, R.L., Fer, M.F., Oldham, R.K.: Cyclophosphamide, Doxorubicin, and Cis- Platinum in the treatment of advanced non-small cell lung carcinoma. *Cancer Treat. Rep.*, 65:941-945, 1981.
99. Oldham, R.K., Julian, C.G., Burnett, L.S., Richardson, R.L., Hande, K.R., Greco, F.A.: Combination chemotherapy and restaging of advanced ovarian carcinoma. In Whitehouse, M. and Williams, C. (Eds): Recent Advanced in Clinical Oncology. London, England, Churchill Livingstone, 165-179, 1982.
100. Dooley, W.C., Oldham, R.K.: Possible association between radiation exposure and chromosome changes. *Lancet*, 2(8185):98, 1980.
101. Fer, M.F., Greco, F.A., Haile, K.L., Rosenblatt, P.A., Johnson, R.L., Glick, A.D., Oldham, R.K.: Unusual survival after pulmonary artery sarcoma. *South. Med. J.*, 74:624-627, 1981.
102. Greco, F.A., Julian, C.G., Richardson, R.L., Burnett, L., Hande, K.R., Oldham, R.K.: Advanced ovarian cancer: brief intensive combination chemotherapy and second look operation *Obstet. Gynecol.*, 58:199-205, 1981.
103. Greco, F.A., Oldham, R.K., Clinical management of patients with small cell lung cancer. In Greco, F.A., Oldham, R.K., Bunn, P.A. (Eds.): *Small Cell Lung Cancer*. I New York, Grune and Stratton, 353-379, 1981.
104. Greco, F.A., Hainsworth, J.D., Sismani, A., Richardson, R.L., Hande, K., Oldham, R.K.: Hormone production and paraneoplastic syndromes. In Greco, F.A., Oldham, R.K., Bunn, P.A. (Eds.): *Small Cell Lung Cancer*. New York, Grune and Stratton, 177-223, 1981.
105. Forbes, J.T., Greco, F.A., Oldham, R.K.: Immunobiology of small cell lung cancer. In Greco, F.A., Oldham, R.K., Bunn, P.A. (Eds.): *Small Cell Lung Cancer*. New York, Grune and Stratton, 327-353, 1981.
106. Oldham, R.K.: Biological response modifier therapy: An overview, *The Cancer Bulletin*, 33: 244-250, 1981.
107. Lyles, J.N., Burish, T.G., Krozely, M.G., and Oldham, R.K.: Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. *J. Con. Psychol.*, 50: 509-524, 1982.
108. Hande, K.R., Oldham, R.K., Fer, M.F., Richardson, R.L., and Greco, F.A.: Randomized study of high-dose vs. low-dose methotrexate in the treatment of extensive stage small cell lung cancer. *Am. J. Med.* 73: 413-419, 1982.
109. Oldham, R.K.,: Biological Response Modifier Program and cancer chemotherapy. *Int. J. Tiss. React.*, IV (3) 173-188, 1982.
110. Fidler, I.J., Berendt, M. and Oldham, R.K.,:The rationale for and design of screening assays for the assessment of biological response modifier for cancer treatment. *J. Biol. Response Modif.*, 1:15-26, 1982.
111. Knost, J.A., Sherwin, S., Abrams, P., and Oldham, R.K.: Increased steroid dependence after recombinant leukocyte interferon therapy. *Lancet*. II (8258):1287-1288, 1981.

112. Fer, M.F., McKinney, T.W., Richardson, R.L., Hande, K.R., Oldham, R.K., Greco, F.A.: Cancer and the kidney: renal complications of neoplasms. *Am. J. Med.* 71(4): 704-718, 1981.
113. Wright, P., Field, R., Mountain, C., Cooper, J., Eagan, R., Ginsberg, R., Gail, M., Hill, A., Holmes, E., Lukeman, J., McGuire, W., Oldham, R.K., Pearson, G.: A prospective double-blind clinical trial of intrapleural *Bacillus calmette guerin* (BCG) in patients with stage I and nonsmall cell lung cancer. *In* Salmon, S. and Jones, Stephen (Eds.): *Adjuvant Therapy of Cancer III*. New York, Grune and Stratton, 265-276, 1981.
114. Oldham, R.K.: Biological Response Modifier Program, *J. Biol. Response Modif.*, 1: 81-100, 1982.
115. Sherwin, S., Fein, S., Whisnant, J., Oldham, R.K.: Phase I Trials of recombinant and nonrecombinant alpha interferons in cancer patients. *In* Merigan, T.C., and Friedman, R.M. (Eds) *Interferons*, Vol XXV. New York, Academic Press, 443-447, 1982.
116. Maluish, A.E., Conlon, J., Ortaldo, J.R., Sherwin, S.A., Leavitt, R., Fein, S., Weirnik, P., Oldham, R.K., and Herberman, R.B.: Modulation of NK and Monocyte activity in advanced cancer patients receiving interferon. *In* Merigan, T.C., and Friedman, R.M., (Eds): *Interferons*, Vol. XXV. New York, Academic Press, 377-386, 1982.
117. Oldham, R.K.: Journal of Biological Response Modifiers: Why another journal?. *J. Biol. Response Modif.*, 1:1-2, 1982.
118. Kuzur, M.E., Cobleigh, M.A., Greco, F.A., Einhorn, L.H., and Oldham, R.K.: Endodermal sinus tumor of the mediastinum. *Cancer*, 50: 766-774, 1982.
119. Sherwin, S.A., Knost, J.A., Fein, S., Abrams, P.G., Foon, K.A., Ochs, J.J., Schoenberger, C., Maluish, A.E., and Oldham, R.K.: A multiple dose Phase I trial of recombinant leukocyte A interferon in cancer patients. *J. Am. Med. Assoc.* 248: 2461- 2466, 1982.
120. Oldham, R.K., Gail, M.H., Baker, M.A., Forbes, J.T., Heineman, W., Hersh, E., Holmes, E.C., Ritts, R.E., Wright, P.W., and the Lung Cancer Study Group: Immunological studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. *Cancer Immunol. Immunother.*, 13:164-173, 1982.
121. Oldham, R.K.: Natural killer cells: History and significance, *J. Biol. Response Modif.*, 1:217-231, 1982.
122. Fer, M.F., Greco, F.A., Oldham, R.K.: Introduction. *In* Fer, M.F., Greco, F.A., and Oldham, R.K.(Eds): *Poorly Differentiated Neoplasms and Tumor of Unknown Origin*, Seminars in Oncology, New York, Grune and Stratton; Vol.9, No.4, 393-395, 1982.
123. Greco, F.A., Oldham, R.K., Fer, M.F.: The extragonadal germ cell cancer syndrome. *In* Fer, M.F., Greco, F.A., Oldham, R.K., (Eds): *Poorly Differentiated Neoplasms and Tumors of Unknown Origin*, Seminars in Oncology, Vol.9, No.4, New York, Grune and Stratton, 448-455, 1982.
124. Fer, M.F., Sherwin, S.A., Oldham, R.K., Greco, F.A., Matthews, M.J.: Poorly differentiated lung cancer. *In* Fer, M.F., Greco, F.A., and Oldham, R.K. (Eds): *Poorly Differentiated Neoplasms and Tumors of Unknown Origin*, Seminars in Oncology, Vol.9, No.4, New York, Grune and Stratton, 456-466, 1982.
125. Key, M.E., Bernhard, M.I., Hoyer, L.C., Foon, K.A., Oldham, R.K., and Hanna, Jr., M.G.: Guinea pig 10 hepatocarcinoma model for monoclonal antibody serotherapy: *In vivo* localization of a monoclonal antibody in normal and malignant tissues. *J. Immunol.*, 139: 1451-1457, 1983.
126. Foon, K.A., Bernhard, M., Oldham, R.K.: Monoclonal antibody therapy: assessment by animal tumor models. *J. Biol. Response Modif.*, 1:277-304, 1982.

127. Fer, M.F., McKinney, T.D., Richardson, R.L., Hande, K.R., Oldham, R.K., Greco, F.A.: Cancer and the Kidney: Renal Complications of Neoplasms. In Clark, Cumley, Kickey (Eds): 1982 Year Book of Cancer. Chicago, Yearbook Medical Publishers 286- 288, 1983.
128. Oldham, R.K. and Smalley, R.V.: Immunotherapy: The old and the new. *J. Biol. Response Modif.*, 2:1-37, 1983.
129. Oldham, R.K.: Guest Editorial: Biological Response Modifiers. *J. Natl.Cancer Inst.*, 70:789-796, 1983.
130. Oldham, R.K.: Biological Response Modifiers Program. In Hadden, J.W., Chedid, P., Spreafico, F., Willoughby, D., (Eds): *Advances in Immunopharmacology 2.*, London, Pergamon Press, pp. 655-660, 1982.
131. Sherwin, S.A., Mayer, D., Ochs, J.J., Abrams, P.G., Knost, J.A., Foon, K.A., Fein, S. and Oldham, R.K.: Recombinant leukocyte A interferon in advanced breast cancer; Results of a Phase II efficacy trial. *Annals Int. Med.*, 98: 598-602, 1983.
132. Herberman, R.B. and Oldham, R.K.: Cell-mediated cytotoxicity against human tumors: Lessons learned and future prospects. *J. Biol. Response Modif.*, 2:111-120, 1983.
133. Oldham, R.K.: Toxic effects of interferon. *Science*, 219: 902, 1983.
134. Oldham, R.K.: Biologicals: New horizons in pharmaceutical development. *J. Biol. Response Modif.*, 2:199-206, 1983.
135. Maluish, A.E., Ortaldo, J.R., Conlon, J.C., Sherwin, S.A., Leavitt, R., Strong, D.M., Weirnik, P., Oldham, R.K. and Herberman, R.B.: Depression of natural killer cytotoxicity following in vivo administration of recombinant leukocyte Interferon. *J. Immunol.*, 131:503-507, 1983.
136. Oldham, R.K.: Monoclonal antibodies as anticancer agents. In Klein, T., Spector, S., Szentivanyi, A., and Friedman, H. (Eds): *Biological Response Modifiers in Human Oncology and Immunology*, New York, Plenum Press, 45-58, 1983.
137. Knost, J.A., Sherwin, S.A., Abrams, P.G., Ochs, J.J., Foon, K.A., Williams, R., Tuttle, R. and Oldham, R.K.: The treatment of cancer patients with human lymphblastoid interferon: A comparison of two routes of administration. *Cancer Immunol. and Immunother.*, 15:144-148, 1983.
138. Stevenson, H.C., Beman, J.A., and Oldham, R.K.: The design of a cytopheresis program for cancer immunology research. *Plasma Therapy*. 4:57-63, 1983.
139. Hanna, Jr., M.G., Key, M.E., Oldham, R.K.: Biology of cancer therapy: Some new insights into adjuvant treatment of metastatic solid tumors. *J. Biol. Response Modif.*, 4:295-309, 1983.
140. Bernhard, M.I., Foon, K.A., Oeltmann, T.N., Key, M.E., Hwang, K.M., Clarke, G.C., Christensen, W.L., Hoyer, L.C., Hanna, Jr., M.G. and Oldham, R.K.: Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. *Cancer Res.* 43:4420-4428, 1983.
141. Oldham, R.K.: Biological Response Modifiers Program. *Cancer Treat. Symposia*, 1:19-27, 1983.
142. Thurman, G.B., Stull, H.B. and Oldham, R.K.: The effects of human interferon on the migration of guinea pig peritoneal exudate cells. In Oppenheim, J.J. and Cohn, S. (Eds): *Interleukines, and Cytokines*, New York, Academic Press, 277-286, 1983.
143. Oldham, R.K.: Current status of monoclonal antibodies in cancer therapy. *Clinical Immunology Newsletter* 14:132-136, 1983.

144. Abrams, P.G., Knost, J.A., Clarke, G., Wilburn, S., Oldham, R.K. and Foon, K.A.: Determination of the optimal human cell lines for human hybridomas. *J. Immunol.* 131:1201-1204, 1983.
145. Oldham, R.K., Monoclonal antibodies in cancer therapy. *J. Clin. Onc.* 1:582-590, 1983.
146. Oldham, R.K.: Biological Response Modifiers Program: Subcommittee report. *J. Natl. Cancer Inst. Monograph* 63:235-247, 1983.
147. Smalley, R.V. and Oldham, R.K.: Interferon as a biological response modifying agent in clinical trials. *J. Biol. Response Modif.* 2:401-408, 1983.
148. Maluish, A.E., Ortaldo, J.R., Sherwin, S.A., Oldham, R.K., and Herberman, R.B.: Changes in immunological function in patients receiving natural leukocyte interferon. *J. Biol. Response Modif.* 2:418-427, 1983.
149. Maluish, A.E., Leavitt, R., Sherwin, S.A., Oldham, R.K. and Herberman, R.B. :Effects of recombinant alpha interferon on immune function in cancer patients. *J. Biol. Response Modif.* 2:470-481, 1983.
150. Bernhard, M.I., Hwang, K.M., Foon, K.A., Keenan, M., Kessler, R.M., Frincke, J.M., Tallam, D.J., Hanna, Jr., M.G., Peters, L., Oldham, R.K.: Localization of 111 In- and 125I-labeled monoclonal antibodies in guinea pigs bearing line 10 hepatocarcinoma tumors. *Cancer Res.*, 43:4429-4433, 1983.
151. Akiyama, Y., Miller, P.J., Thurman, G.B., Neubauer, R.H., Oliver, C., Favilla, T., Beman, J.A., Oldham, R.K. and Stevenson, H.C.: Characterization of a human blood monocyte subset with low peroxidase activity. *J. Clin. Invest.*, 72:1093- 1105, 1983.
152. Weinstein, J.N., Steller, M.A., Keenan, A.M., Covell, D.G., Key, M.E., Sieber, S.M., Oldham, R.K., Hwang, K. M. and Parker, R.J.: Monoclonal antibodies in the lymphatics: Selective delivery to lymph node metastases of a solid tumor. *Science*, 222:423-426, 1983.
153. Stevenson, H.C., Miller, P., Akiyama, Y., Favilla, T., Beman, J.A., Herberman, R.B., Stull, H., Thurman, G., Maluish, A., and Oldham, R.K.: A system for obtaining large numbers of cryopreserved human monocytes purifier by leukapheresis and counter-current centrifugation elutriation (CCE). *J. Immunol. Methods.* 62:353-363, 1983.
154. Oldham, R.K.: Biologicals and biological response modifiers: The fourth modality of cancer treatment. *Cancer Treat. Rep.* 68:221- 232, 1984.
155. Foon, K.A., Bunn, P.A., Schroff, R.W., Mayer, D., Hsu,S-M., Sherwin, S.A. and Oldham, R.K.: Monoclonal antibody therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma: Preliminary observations. In Boss B.D. Langman, R.E. and Trowbridge, I.S. and Dulbecco, R. (Eds.): *Monoclonal Antibodies and Cancer.* New York, Academic Press. pp. 39-52, 1983.
156. Foon, K.A., Abrams, P.G., Rossio, J.L., Knost, J.A. and Oldham, R.K.: Human hybridomas: Comparison of human cell lines for production of human hybridomas and development of human hybridomas producing antigen-specific IgG using in vivo immunized peripheral blood cells as fusing partners. In Boss, B.D., Langman, R.E. and Trowbridge, I.S. and Dulbecco, R. (Eds.): *Monoclonal Antibody and Cancer.* New York, Academic Press. pp. 143-155, 1983.
157. Oldham, R.K.: NK cells: Artifact to reality, an odyssey in biology. *Can. Metas. Rev.*, 2:232-336, 1983.
158. Talmadge, J.E., Oldham, R.K. and Fidler, I.J.: Practical considerations for the establishment of a screening procedure for the assessment of biological response modifiers. *J. Biol. Response Modif.*, 3:88-109, 1984.
159. Oldham, R.K., Morgan, A.C., Woodhouse, C.S., Schroff, R.W., Abrams, P.G. and Foon, K.A.: Monoclonal Antibodies in the treatment of cancer: Preliminary observations and future prospects. *Med. Onc. and Tumor Pharm.* 1:51-62, 1984.

160. Smalley, R.V., Foon, K.A., Schroff, R.W., Woodhouse, C., Morgan, A.C. and Oldham, R.K.: Monoclonal antibody therapy NCI (BRMP) supported trials in humans and guinea pigs. In Herberman, R.B., Micksche, M. and Smalley, R.V.(Eds.): Proc. 13th International Congress of Chemotherapy, Alan R. Liss Inc., New York, N.Y., 35-45, 1983.
161. Smalley, R.V., Long, C., Sherwin, S.A. and Oldham, R.K.: Biological response modifiers: Current status and prospects as anticancer agents. In Herberman, R.B. (Eds.): Basic and Clinical tumor Immunology. Netherlands, Martinus Nijhoff Pub. pp. 257-300, 1983.
162. Smalley, R.V., Talmadge, J., Oldham, R.K., and Thurman, G.B.: The thymosins: preclinical and clinical studies with fraction V and alpha-1. *Cancer Treat. Rev.*, 11:69-84, 1984.
163. Oldham, R.K. and Smalley, R.V.: Gamma Interferon: Early studies and potential applications. *Clin. Immunol. Newsletter* 5:69-73, 1984.
164. Talmadge, J.E., Maluish, A.E., Collins, M., Schneider, M., Herberman, R.R., Oldham, R.K., Wiltrout, R.H.: Immunodulation and anti tumor effects of MVE-2 in mice, *J. Biol. Response Modif.* 3:634-652, 1984.
165. Abrams, P.G., Ochs, J.J., Giardina, S.L., Morgan, A.C., Wilburn, S.B., Wilt, A.R., Oldham, R.K. and Foon, K.A.: Production of large quantities of human immunoglobulin in the peritoneum athymic mice: Implications for the development of anti-human idiotype monoclonal antibodies. *J. Immunol.* 132:1611-1613, 1984.
166. Stevenson, H.C., Schlick, E., Griffith, R., Chirigos, M.A., Brown, R., Conlon, J., Kanapa, D.J., Oldham, R.K. and Miller, P.: Characterization of biological response modifier release by human monocytes cultured in suspension in serum free medium. *J. Immunol. Meth.* 70:245-255, 1984.
167. Fer, M.F., Benman, J., Stevenson, H., Maluish, C., Delawter, T., Foon, K.A., Herberman, R., Oldham, R.K., with Terman, D., Young, J., and Daskal, Y.: A trial of autologous plasma perfusion over protein A in patients with breast cancer. *J. Biol. Response Modif.* 3:352-358, 1984.
168. Francisco, R., Omura, G.A., Birch, R., Krauss, S., Oldham, R.K.: Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer. *J. Clin. Onc.* 2:391-395, 1984.
169. Smalley, R.V. and Oldham, R.K.: Biological Response Modifiers: Preclinical evaluation and clinical activity. *CRC Critical Reviews in Oncology/Hematology.* 1:259-280, 1984.
170. Thurman, G.B., Stull, H.B., Miller, P.J., Stevenson, H.C. and Oldham, R.K.: Utilization of purified human monocytes in the agarose droplet assay for measuring migration inhibitory factors. *J. Immunol. Methods.* 65:41-53, 1984.
171. Talmadge, J.E., Lenz, B.F., Collins, M.S., Uithoven, K.A., Schneider, M.A., Adams, J.S., Pearson, J.W., Agee, W.J., Fox, R.E. and Oldham, R.K.: Tumor models to investigate the therapeutic efficiency of immunodulators. Symposium on Models and Methods in the Immunotherapy and Chemotherapy of Cancer. *Behring Inst. Mitt* 74:219-229, 1984.
172. Oldham, R.K.: Introduction, Symposium on ex vivo plasma immunoadsorption and protein A in cancer therapy. *J. Biol. Response Modif.* 3:229-230, 1984.
173. Foon, K.A., Sherwin, S.A., Bunn, P.A., Longo, D. and Oldham, R.K.: Recombinant leukocyte interferon in the treatment of non- Hodgkin's lymphoma, chronic lymphocytic and cutaneous T-cell lymphoma. In Interferon: Research, Clinical Application, and Regulatory Consideration, Zoon, K.A., Noguchi, P.C., and Lui, T.Y. (Eds.) Elsevier Science Publishing. pp.219-227, 1984.
174. Oldham, R.K. and Smalley, R.V.: The role of interferon in the treatment of cancer. In Interferon: Research, Clinical Application, and Regulatory Consideration, Zoon, K.C., Noguchi, P.C., Lui, T.-Y. (Eds.): Elsevier Science Publishing. pp. 191- 205, 1984.

175. Stevenson, H.C., Foon, K.A., Kanapa, D.J., Favilla, T., Beman, J.A., Oldham, R.K.: The potential value of cytopheresis for adoptive immunotherapy of cancer patients. *Plasma Therapy Transfus. Tech.* 5:237-250, 1984.
176. Oldham, R.K., Berneman, L.P.: Lymphokines and other biological response modifiers in the treatment of cancer. Online Publications, Pinner, UK. *Biotech '84*,:Vol.II, A257-284.
177. Oldham R.K.: Small cell Lung Cancer: A Curable Disease. In *Clinics in Oncology*. W.B. Saunders Co. Ltd; S. Spiro (Eds.) 4:153-160, 1985.
178. Talmadge, J.E., Fidler, I.J., and Oldham, R.K.: The NCI preclinical screen of biological response modifiers. *Behring Inst. Mitt.* 74:189-194, 1984.
179. Oldham, R.K., Sherwin, S.A., Maluish, A., Long, W.C., Watson, T. and Foon, K.A.: A Phase I trial of immune interferon: A preliminary report. In Goldstein, A.L. (Ed.): *Thymic Hormones and Lymphokines*, New York, Plenum Press, pp. 497-506, 1984.
180. Hwang, K.M., Foon, K.A., Cheung, P.H., Pearson, J.W. and Oldham, R.K.: Selective antitumor effect on L-10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. *Cancer Res.* 44:4578-4586, 1984.
181. Oldham, R.K., Thurman, G.B., Talmadge, J.E., Stevenson, H.C. and Foon, K.A.: Lymphokines, monoclonal antibodies and other biological response modifiers in the treatment of cancer. *Cancer*, 54:2795-2810, 1984.
182. Foon, K.A., Schroff, R., Bunn, P.A., Mayer, D., Abrams, P.G., Fer, M.F., Ochs, J., Bottino, G., Sherwin, S.A., Carlo, D.J., Herberman, R.B. and Oldham, R.K.: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. *Blood.* 66:1085-1093, 1984.
183. Bunn, P.A., Foon, K.A., Ihde, D.C., Longo, D.L., Eddy, J., Winker, C.F., Veach, S.R., Zeffren, J., Sherwin, S.A. and Oldham, R.K.: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. *Annals of Int. Med.* 101:484-487, 1984.
184. Fer, M.F., Bottino, G.C., Sherwin, S.A., Hainsworth, J.D., Abrams, P.G., Foon, K.A., Oldham, R.K.: Atypical tumor lysis syndrome in a patient with T-cell lymphoma treated with recombinant leukocyte interferon. *Am. J. Med.* 77:953-956, 1984.
185. Schroff, R.W., Farrell, M.M., Klein, R.A., Oldham, R.K. and Foon, K.A.: T65 antigen modulation in a phase I monoclonal antibody trial with chronic lymphocytic leukemia patients, *J. Immunol.* 133:1641-1648, 1984.
186. Stevenson, H.C., Ochs, J.J., Halverson, L., Oldham, R.K., Sherwin, S.A., Foon, K.A.: Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma, Dramatic responses with resolution of pulmonary complications. *Am. J. Med.* 77:355-358, 1984.
187. Morgan, A.C., Jr., Woodhouse, C.S., Knost, J.A., Abrams, P.G., Clarke, G.C, Arthur L.O., McIntyre, R., Ochs, J.J., Foon, K.A., and Oldham, R.K.: Monoclonal antibodies to human colorectal tumor-associated antigens: Improved elicitation and subclass restriction. *Hybridoma.* 3:233-245, 1984.
188. Foon, K.A., Sherwin, S.A., Abrams, P.G., Longo, D.L., Fer, M.F., Stevenson, H.C., Ochs, J.J., Bottino G.C., Schoenberger, C.S., Zeffren, J., Jaffe, E., Oldham, R.K.: Treatment of advanced non- Hodgkin's lymphoma with recombinant leukocyte A interferon. *New England J. of Med.* 311:1148-1152, 1984.
189. Oldham, R.K., Foon, K.A., Morgan, A.C., Woodhouse, C.S., Schroff, R.W., Abrams, P.G., Fer, M., Schroeberger, C.S., Farrell, M., Kimball, E., Sherwin, S.A.: Monoclonal antibody therapy of malignant melanoma: In vivo localization in cutaneous metastasis after intravenous administration. *J. Clin. Onc.* 2:1235-1242, 1984.

190. Perez, C.A., Einhorn, L., Oldham, R.K., Greco, G.A., Cohen, H.J., Silbermena, H., Krauss, S., Hornback, N., Comas, F., Omura, G., Salter, M., Keller, J.W., McLaren, J., Kellermeyer, R., Storaasli, J., Birch, R., Dandy, M. and the Southeastern Cancer Study Group: Randomized trial of radiotherapy to the thorax in limited cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation, a preliminary report. *J. of Clin. Oncol.* 2:1200-1208, 1984.
191. Oldham, R.K., Chretien, P.B.: Summary: Clinical Applications; *J. of Biol. Res. Modif.* Vol.3, No.6, 629-636, 1984. *In* Goldstein, A.L. (Ed.): *Thymic Hormones and Lymphokines*, New York, Plenum Press, pp. 497-506, 1984.
192. Gail, M.H., Eagan, R.T., Feld, R., Ginsberg, R., Goodell, B., Hill, L., Holmes, E.C., Lukeman, J.M., Mountain, C.F., Oldham, R.K., Pearson, F.G., Wright, P.W., Lake, W.H., and the Lung Cancer Study Group: Prognostic factors in patients with resected stage I non-small cell lung cancer; a report from the Lung Cancer Study Group. *Cancer*, 54: 1802-1813, 1984.
193. Sherwin, S.A., Foon, K.A, Abrams, P.G., Heyman, M.R., Ochs, J.J., Watson, T., Maluish, A., Oldham, R.K.: A preliminary phase I trial of partially purified interferon-gamma in patients with cancer. *J. Biol. Response Modif.* 3: 599-607. 1984.
194. Stevenson, H.C., Bovini, E., Favilla, T., Miller, P., Akiyama, Y., Hoffman, T., Oldham, R.K.: Characterization of purified cryopreserved human monocytes in assays of superoxide production, accessory cell function, chemotaxis, and in fluorescent cell sorter analysis. *J. Leuk. Biology* 36:521-531. 1984.
195. Schroff, R.W.Jr., Foon, K.A., Beatty, S.M., Oldham, R.K., Morgan, A.C.: Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. *Cancer Res.* 44:879-885, 1985.
196. Woodhouse, C.S., Seiler, C., Morgan, A.C.Jr., Oldham, R.K.: Immunohistochemical detection of the Ca antigen in normal and tumor tissues of humans by use of Cal monoclonal antibody. *J. Nat. Cancer Inst.* 74:383-389, 1985.
197. Foon, K.A., Bottino, G.C., Abrams, P.G., Fer, M.F., Longo, D.L., Schoenberger, C.S., Jones, G., Oldham, R.K.: Phase II trial recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. *Am. J. Med.* 78:216-220, 1985.
198. Schroff, R.W., Woodhouse, C.S., Foon, K.A., Oldham, R.K., Farrell, M.M., Klein, R.A., Morgan, A.C.Jr.: Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250K Dalton Melanoma Associated Antigen. *J. Nat. Cancer Inst.* 74:299-306, 1985.
199. Morgan, A.C.Jr., Pavanadasivam, G., Hwang, K.M., Woodhouse, C.S., Schroff, R.W., Foon, K.A. and Oldham, R.K.: Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen. *In*: Peeters H (Ed) *Protides of the Biological Fluids.* 32:773-777, Pergamon Press, London, 1985.
200. Oldham, R.K.: Biological response modifiers as anticancer agents. Harrap, K.R., Davis, W., Calvert, A.H. (Eds) *Cancer Chemotherapy and Selective Drug Development.* Martinus Nijhoff, Boston. 1984.
201. Smalley, R.V., Talmadge, J., Oldham, R.K. and Thurman, G.B.: The Biological Response Modifiers Program: Preclinical and Clinical Studies with Thymosin Preparations. *In* Byrom, N.A. and Hobbs, J.R. (Eds): *Thymic Factor Therapy.* London, Academic Press, pp 399-409, 1984.
202. Smalley, R.V., Talmadge, J.E., Oldham, R.K. and Thurman, G.B.: The Biological Response Modifiers Program: Preclinical and clinical studies with thymosin preparations. *Cancer Treat. Rev.*, 11:67-84, 1984.
203. Thurman, G.B., Braude, I.A., Gray, P.W., Oldham, R.K. and Stevenson, H.C.: MIF-like activity of natural and recombinant human interferon and their neutralization by monoclonal antibody. *J. of Immun.*, 134:305-309, 1985.
204. Oldham, R.K.: Biologicals and Biological Response Modifiers: New approaches to cancer treatment. *Cancer Investigation*, 3:53-70, 1985.

205. Oldham, R.K.: The Cure for Cancer. *J. Biol. Response Modif.* 4:111-116, 1985.
206. Oldham, R.K.: Biologicals and Biological Response Modifiers: The design of Clinical Trials. *J. Biol. Response Modif.* 4:117-128, 1985.
207. Oldham, R.K.: Whose Rights Come First? *J. Biol. Response Modif.* 4:211-212, 1985.
208. Oldham, R.K. and Smalley, R.V.: Biologicals and Biological Response Modifiers in Cancer Treatment. *In* DeVita, Hellman, and Rosenberg (Eds.): *Cancer-Principles and Practice of Oncology*. J.B. Lippincott, pp. 2223-2245, 1985.
209. Stevenson, H.C., Miller, P., Huffer, T., Oldham, R.K., Kanapa, D.J., Sen, A.: Characterization of H-Uridine incorporation and messenger RNA synthesis observed in human monocytes activated to secrete alpha interferon of fibroblast growth factor. *J. Leuk. Biol.* 37:585-595, 1985.
210. Fer, M.F. and Oldham, R.K.: Protein A immunoadsorption/ immunoactivation: a critical review. *In* Salinas, F.A. and Hanna, M.G. (Eds.): *Immune Complexes and Human Cancer, Contemporary Topics in Immunobiology*, Vol.15. Plenum Publishing Company, New York, pp. 257-276, 1985.
211. Oldham, R.K.: Biologicals and biological response modifiers: New strategies for clinical trials. *In* Finter, N.B. and Oldham, R.K. (Eds.): *Interferons, IV*. Elsevier Science Publishers B.V. pp. 235-249, 1985.
212. Oldham, R.: Inf: A model for future biologicals. *In* Burke, D, Cantell, K., Gresser, I., De Maeyer, E., Landy, M, Revel, M. and Vilcek, J.(Eds.): *Inf. VI*. pp. 127-143, Academic Press, 1985.
213. Sherwin, S.A. and Oldham, R.K.: The new concept of biological response modifiers. *In* Mathe (Ed.): *Current Drugs and Methods of Cancer Treatment*. New York, Masson Publishers, Inc. pp. 133-135, 1985.
214. Oldham, R.K., Finter, N.B.: Biologicals and biological response modifiers: Results of some further studies with interferon in patients with cancer. *In* *Interferons, IV*. (N.B. Finter and R.K. Oldham Eds.) Elsevier Biomedical Press, Amsterdam pp. 359-361, 1985.
215. Oldham R.K.: Antibody-drug and antibody toxin conjugates, Reif A.E., Mitchell M.S. (Eds) *Immunity to Cancer*, Academic Press, New York. pp. 575-586, 1985.
216. Abrams, P.G., Oldham, R.K.: Monoclonal antibody therapy of solid tumors. *In* Foon, K.A., Morgan, A.C. Jr., (Eds.) *Monoclonal Antibody Therapy of Human Cancer*. Martinus Nijhoff. pp. 103- 120, 1985.
217. Talmadge, J.E., Fidler, B.F., Lenz, D.M., Litton, C.W., Riggs, Guo, S., Simmons, R., Oldham, R.K.: Treatment of Metastasis: Problems and Prospects. *In* Hellmann, K., Eccles, S.A.,(Eds.) *Proceedings of the International Meeting London*. Taylor Frances Ltd. Philadelphia, p. 153, 1985.
218. Hwang, K.M., Fodstad, O., Oldham, R.K., Morgan, A.C.: Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen. *Cancer Res.* 45:4150-4155, 1984.
219. Oldham, R.K.: Future perspectives in the clinical application of lymphokines. *In* Sorg, C., Schimpe, A. (Eds.): *Cellular and Molecular Biology of Lymphokines*. Academic Press, New York pp. 735-748, 1985.
220. Hanna, M.G., McCabe, R.P. and Oldham, R.K.: Immunotherapy of Cancer. *Clin. Immunol. Newsletter.* 6:156-159, 1985.
221. Oldham, R.K.: Advances in cancer detection. *Bio Expo '85 Symposium*, pp. 436-441, 1985.
222. Oldham, R.K.: Biologicals for cancer treatment: Interferons. *Hospital Practice*, 20:72-91, 1985.



223. Abrams, P.G., Morgan, A.C., Schroff, R.W., Woodhouse, C.S., Carrasquillo, J., Stevenson, M.F. Fer, Oldham, R.K., Foon, K.A.: Monoclonal Antibodies in Cancer Therapy: Drug-Antibody Conjugates. In Localization and biodistribution studies of a monoclonal antibody in patients with melanoma. Reisfield and Sell (Eds.). Alan R. Liss, New York 27:233-236, 1985.
224. Giardina, S.L., Schroff, R.W., Woodhouse, C.S., Golde, D.W., Oldham, R.K., Cleary, M.L., Sklar, J., Foon, K.A.: Detection of two distinct malignant B-cell clones in a single patient using anti-idiotypic monoclonal antibodies and immunoglobulin gene arrangement. *Blood*, 66:1017-1021, 1985.
225. Oldham, R.K.: Biological response modifiers: Introduction. In Torrence, P.F. (Eds.) Biological Response Modifiers, Academic Press, New York, pp. 1-20, 1985.
226. Oldham, R.K., West, W.H.: Application of monoclonal antibodies in imaging and therapy. *Clinical and Experimental Pathology of Lung Cancer*, Martinus Nijhoff Publishers, pp. 149-163, 1986.
227. Fer, M.F., Abrams, P.G., Oldham, R.K., Sherwin, S.A., Mulshine, J.L., Greco, F.A., Matthews, M.J.: Poorly differentiated lung cancer. In Fer, M.F., Greco, F.A., Oldham, R.K. (Eds.) Poorly Differentiated Neoplasms and Tumors of Unknown Origin. Grune and Stratton, pp. 271-292, 1986.
228. Fer, M.F., Greco, F.A., Oldham, R.K.: Intro. In Fer, M.F., Greco, F.A., Oldham, R.K. (Eds.) Poorly Differentiated Neoplasms and Tumors of Unknown Origin. Grune and Stratton, pp. 1-2, 1986.
229. Oldham, R.K., Fidler, I.J., Talmadge, J.E.: Screening of biologicals and biological response modifiers. *Aktuelle Onkologie* 24. In P. Schuff-Werne and K. Pfitzenmaier (Eds.) W. Zuckschwerdt Verlag Munchen. pp. 93-109, 1985.
230. Oldham, R.K.: Overview of the clinical use of lymphokines in clinical trials. *Lymphokines The New Super Drugs?* IBC Technical Services Ltd. Publication, 1986.
231. Oldham, R.K.: The government-academic "industrial" complex. *J. Biol. Response Res.* 5:109-111, 1986.
232. Smalley, R.V., Oldham, R.K.: Phase I trials of biological response modifiers. *Drugs Exptl. Clin. Res.*, 12:31-39, 1986.
233. Oldham, R.K.: Biologicals and other biological response modifiers: preclinical and clinical assessment of cancer treatment. In *Infections in the Immunocompromised Host*. Plenum Press, pp. 185-204, 1986.
234. Foon, K.A., Sherwin, S.A., Abrams, P.G., Holmes, P., Maluish, A.E., Oldham, R.K., Herberman, R.B.: A phase I trial of recombinant gamma interferon in patients with cancer. *Ca Immun. Immunother.* 20:193-197, 1985.
235. Hwang, K.M., Keenan, A.M., Frincke, J., David, G., Pearson, J., Oldham, R.K., Morgan, A.C. Jr.: Dynamic interaction of <sup>111</sup>indium-labeled monoclonal antibodies with surface of solid tumors visualized in vivo by external scintigraphy. *J. Nat. Cancer Inst.*, 76:849-855, 1986.
236. Oldham, R.K.: Profits: Who Benefits? *J. Biol. Response Modif.* 5:203-205, 1986.
237. Talmadge J.E., Herberman, R.B., Chirigos, M.A., Maluish, A.E., Schneider, M.A., Adams, J.S., Philips, H., Thurman, G.B., Varesio, L., Long, C., Oldham, R.K., Wiltout, R.H.: Hyporesponsiveness to Augmentation of Murine Natural Killer Cell Activity in Different Anatomical Compartments by Multiple Injections of Various Immunomodulators Including Recombinant Interferons and Interleukin 2. *J. Immunol.* 135:2483-2491, 1985.
238. Oldham, R.K.: Monoclonal antibodies. In Nathanson L. (Ed.) *Management of Advanced Melanoma. Contemporary Issues in Clinical Oncology*. Churchill Livingstone, Inc. New York, pp. 195-207, 1986.
239. Oldham, R.K.: Biotherapy: The fourth modality of cancer treatment. *Cancer: Perspective For Control Symposium, J. Cell. Physiol. Supplement.* 4:91-99, 1986.

240. Oldham, R.: Biotherapy: The fourth modality of cancer treatment. In Mak, T., Sun, T.(Eds.): Cancer: Perspective For Control Symposium. Alan R. Liss, Inc., New York, pp. 91-99, 1986.
241. Carrasquillo, J.A., Bunn, P.A. Jr., Kennan, A.M., Reynolds, J.C., Schroff, R.W., Foon, K.A., Ming-Hsu, S., Gazdar, A.F., Mulshine, J.L., Oldham, R.K., Perentsis, P., Horowitz, M., Eddy, J., James, P., Larson, S.M.: Radioimmuno-detection of cutaneous T-cell lymphoma with <sup>111</sup>In-T101 monoclonal antibody. *New Engl. J. Med.* 315:673-680, 1986.
242. Sherwin, S.A., Foon, K.A. and Oldham, R.K.: Animal tumor models for biological response modifier therapy: an approach to the development of monoclonal antibody therapy in humans. In Carter, S. and Hellmann, K. (Eds.): *Fundamentals of Cancer Chemotherapy*. New York, McGraw Hill Publishers, 1987.
243. Talmadge, J.E., Lenz, B.F., Klabansky, R., Simon, R., Riggs, C., Guo, S., Oldham, R.K., Fidler, I.J.: Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. *Cancer Research*, 46:1160-1163, 1986.
244. Oldham, R.K.: Monoclonal antibodies and immunoconjugates as anti-cancer agents. In Szentivanyi, A., Maurer, P., Janicki, B.W. (Eds.): *Antibodies-Structure, Synthesis, Function and Immunologic Intervention in Disease*. Plenum Press, pp. 191-202, 1987.
245. Oldham, R.K.: Patient-funded cancer research. *N. Engl. J. Med.* 316:46-47, 1987.
246. Oldham, R.K.: Monoclonal antibodies as anticancer agents. In Klein, T., Specter, S., Szentivanyi, A., Freidman, H. (Eds.): *Biological Response Modifiers in Human Oncology and Immunology*. Plenum Press, pp. 45-58, 1983.
247. Oldham, R.K.: Perspectives on the use of immunotoxins in clinical medicine. In: *Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer*. Vogel C-W (Ed.), New York, Oxford Univ. Press, pp. 281-289, 1987.
248. Morgan, A.C., Pearson, J.W., Oldham, R.K.: Preclinical evaluation of immunoconjugates. In: *Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer*. Vogel C-W (Ed.), Oxford Univ. Press, pp. 241-258, 1987.
249. West, W.H., Tauer, K.W., Yannelli, J. R., Marshall, G.D., Orr, D.W., Thurman, G.B., Oldham, R.K.: Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. *New Engl. J. Med.* 316(15):898-905, 1987.
250. Oldham, R.K.: Immunotherapy: old concepts and new approaches. In: *Present Status of Non-Toxic Concepts in Cancer*. (Eds.) Klippel, K.F., Macher. E. Karger, Ag, Basel, pp. 1-21, 1987.
251. Oldham, R.K.: Monoclonal antibodies: does sufficient selectivity to cancer cells exist for therapeutic application? *J. Biol. Response Modif.*, 6:227-234, 1987.
252. Bonnem, E., Oldham, R.K.: Gamma interferon physiology and potential role in cancer therapy. *J. Biol. Response Modif.*, 6:275-301, 1987.
253. Schroff, R.W., Morgan, A.C. Jr., Woodhouse, C.S., Abrams, P.G., Farrell, M.M., Carpenter, B.E., Oldham, R.K., Foon, K.A.: Monoclonal antibody therapy in malignant melanoma: factors effecting in vivo localization. *J. Biol. Response Modif.*, 6:457- 472, 1987.
254. Paranasivam, G., Pearson, J.W., Bohn, W., Oldham, R.K., Sadoff, J.C., Morgan, A.C., Jr.: Immunotoxins to a human melanoma- associated antigen: comparison of gelonin with ricin and other a-chain conjugates. *Cancer Res.*, 47:3169-3173, June 15, 1987.

255. Yannelli, J.R., Thurman, G.B., Dickerson, S.G., Mrowca, A., Sharp, E. and Oldham, R.K.: An improved method for the generation of human lymphokine activated killer cells. *J. Immunol. Methods.*, 100:137-145, 1987.
256. Oldham, R.K.: Drug development: who foots the bill? *Bio/technology*. 5:648, 1987.
257. Oldham, R.K.: False hope vs. opportunity. *Cope Magazine*, April pp. 66, 1987.
258. Oldham, R.K.: Letter to the Editor: Patient-funded cancer research. *New Engl. J. of Med.*, July 16, 316 pp. 172, 1987.
259. Oldham, R.K., Yannelli, J.R., Thurman, G.B., West, W.H.: An improved method for the generation of human activated killer cells. In: Webb, D.R., Pierce, C.W., Cohen, S. (Eds.) *Molecular Basis of Lymphokine Action*. Humana Press, pp. 393-407, 1987.
260. Oldham, R.K.: Biotherapy: general principles. In: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy*. Raven Press, New York, pp. 1-20, 1987.
261. Oldham, R.K.: Developmental therapeutics and the design of clinical trials. In: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy*. Raven Press, New York, pp. 49-63, 1987.
262. Smalley, R.V., Oldham, R.K.: Chemical inducers of lymphokines. In: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy*. Raven Press, New York, pp. 223-245, 1987.
263. Oldham, R.K.: Immunoconjugates: drugs and toxins. In: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy*. Raven Press, New York, pp. 319-335, 1987.
264. Orr, D.W., Lewis, M., Oldham, R.K.: Cancer biotherapy: 1987 disease-related activity. In: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy*. Raven Press, New York, pp. 469-487, 1987.
265. Oldham, R.K.: Speculations for the nineties. In: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy*. Raven Press, New York, pp. 489-494, 1987.
266. Oldham, R.K., O'Connor, T.E.: TNF as a biological response modifier. *Therapeutic Research*, Vol. 7, No. 2, pp. 125-135, 1987.
267. Oldham, R.K.: Biotherapy: individualized cancer treatment. *Therapeutic Research*, Vol. 7, No. 2, pp. 163-175, 1987.
268. Oldham, R.K.: Patients as Research Partners. In: *The Privatization of Cancer Research*. City Club of Cleveland, Cleveland, OH. *Vital Speeches of the Day*. pp. 763-766, October 1, 1987.
269. Oldham, R.K.: Biotherapy in cancer: present status and clinical outlook. In: Klippel, K.F., Harzmann, R. (Eds.), *Immunotherapy of Urologic Tumors*. SMVerlags GmbH, Germany, pp. 7-24, 1987.
270. Dupere, S.L., O'Connor, T.E., Oldham, R.K.: Clinical Applications of Lymphokines. *Revisiones on Cancer (Madrid)*, Vol.1 (3):113-122, 1987.
- 270A Oldham, R.K.: Whose Life Is It Anyway? *Wall Street Journal*. April 24, 1987.
271. Dupere, S.L., O'Connor, T.E., Oldham, R.K.: Lymphokines/cytokines: biotherapeutic applications. Estratto dalla rivista EOS n.3, vol. VIII, 201-210, 1988.
272. Carrasquillo, J.A., Abrams, P.G., Schroff, R., Reynolds, J., Woodhouse, C.S., Morgan, A.C., Keenan, A., Foon, K.A., Perentesis, P., Marshall, S., Horowitz, M., Szymendera, J., Oldham, R.K., Larson, S.M.: Effect of antibody dose on the imaging and biodistribution of indium-111 9.2.27 anti-melanoma monoclonal antibody. *J. Nucl.*

- Med. January, 29(1):39-47, 1988.
273. Oldham, R.K.: Interferon treatment of non-hodgkin's lymphoma and myeloma: a model for biotherapy. In: Clinical Aspects of Interferons. Revel, M. (Ed.), Kluwer Academia Publishers, Boston, pp. 109-120, 1988.
  274. Oldham, R.K.; Lewis, M.; Orr, D.W.: "Cancer Biotherapy" (Part I) In: Professional Education Newsletter, Vol. XVII, Issue 3, Tennessee Division of the American Cancer Society, pp. 1-14, 1988.
  275. Oldham, R.K.; Lewis, M.; Orr, D.W.: "Cancer Biotherapy" (Part II) In: Professional Education Newsletter, Vol. XVII, Issue 4, Tennessee Division of the American Cancer Society, pp. 1-18, 1988.
  276. Smalley, R., Oldham, R.K.: Newer methods of cancer screening and treatment with biologics. In: Grundfest-Broniatowski, S., Esselstyn, Jr., C.: Controversies in Breast Disease: Diagnosis and Treatment. Marcel Dekker, Inc. New York. pp.481-505, 1988.
  277. Oldham, R.K.: Who pays for new drugs? Nature, 332(28):795, 1988.
  278. Oldham, R.K.: Monoclonal antibody therapy. In Biological Response Modifiers and Cancer Research. (Ed.) Chiao, J.W., Marcel Dekker, Inc., Vol. 40 pp. 3-16, 1988.
  279. Oldham, R.K. Therapeutic monoclonal antibodies: effects of tumor cell heterogeneity. In: Therapeutic Monoclonal Antibodies: Effects of Tumor Cell Heterogeneity. S. Karger Ag. Cancer Treatment Symposium (Germany), 1988.
  280. Avner, B., Avner, B.P., Gaydos, B., Liao, S.K., Thurman, G.B., Oldham, R.K.: Characterization of a method using viable human target cells as the solid phase in a cell concentration fluorescence immunoassay (CCFIA) for screening of monoclonal antibodies and hybridoma supernatants. J. Immunol. Methods, 113:123-135, 1988.
  281. Yannelli, J.R., Thurman, G.B., Mrowca-Bastin, A., Pennington, C.S., West, W.H., Oldham, R.K.: Enhancement of human lymphokine- activated killer cell cytolysis and a method for increasing lymphokine-activated killer cell yields to cancer patients. Cancer Research, 48:5696-5700, 1988.
  282. Oldham, R.K.: Regulatory Hierarchies. (Editorial) Mol. Biother., 1(1):3-6, 1988.
  283. O'Connor, T.E., West, W.H., Marshall, G.D., Orr, D.W., Lewis, M., Oldham, R.K.: Principles of biotherapy and its application to the treatment of disseminated renal cancer. Seminars in Surgical Oncology. 4:155-160, 1988.
  284. Oldham, R.K.: Fundamentally flawed? Mol. Biother., 1(2):58-60, 1988.
  285. Oldham, R.K., Lewis, M., Orr, D.W., Avner, B.P., Liao, S.K., Ogden, J.R., Avner, B., Birch, R.: Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies. Mol. Biother., 1(2):103-113, 1988.
  286. Avner, B.P., Liao, S.K., Avner, B., DeCell, K., Oldham, R.K.: Therapeutic murine monoclonal antibodies developed for individual cancer patients. J. Biol. Response Modif., 8(1):25- 36, 1989.
  287. Ogden, J.R., Leung, K., Kundra, S.A., Telander, M.W., Avner, B.P., Liao, S.K., Thurman, G.B., Oldham, R.K.: Immunoconjugates of doxorubicin and murine antihuman breast carcinoma monoclonal antibodies prepared via an n-hydroxysuccinimide active ester intermediate of cis-aconityl-doxorubicin: preparation and in vitro cytotoxicity. Mol. Biother., 1(3):170-174, 1989.
  288. Liao, S.K., Meranda, C., Avner, B.P., Romano, T., Husseini, S., Kimbro, B., and Oldham, R.K.: Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies. Cancer Immunol. Immunother., 28:77- 86, 1989.
  289. Oldham, R.K.: Why deny health care? The Freeman. March, pp. 94- 95, 1989.

290. Oldham, R.K., Maleckar, J.R., Yannelli, J.R., West, W.H.: IL-2: a review of current knowledge. In: Clinical Courier. Amsterdam Conference Proceedings. Vol. 7(2):2-3, 1989.
291. Orr, D.W., Oldham, R.K., Lewis, M., Ogden, J., Liao, S.K., Leung, K., Dupere, S., Birch, R., Avner, B.P.: Phase I trial of mitomycin-c immunoconjugate cocktails in human malignancies. Mol. Biother., Vol. 1(4): 229-240, 1989,
292. Oldham, R.K.; Avent, R.A.: Clinical research: who pays the bills? Oncology Issues, Vol. 4(2):13-14, 1989.
293. Oldham, R.K.: Clinical research in cancer: a time for consensus. Pharmaceutical Executive, July, pp. 23-24, 1989.
294. Maleckar, J.R., Friddell, C.S., Lewko, W.M., Yannelli, J.R., West, W.H., Oldham, R.K.: Tumor-derived activated cells: culture conditions and characterization. In: Stevenson, H.C. (Ed.), Adoptive Cellular Immunotherapy of Cancer. Marcel Dekker, Inc. New York, pp. 159-173, 1989.
295. Yannelli, J.R., Jadus, M.R., Beckner, S., Lacerna, L., Oldham, R.K.: Clinical/technical challenges in adoptive cellular immunotherapy: in vitro culture techniques. In: Stevenson, H.C. (Ed.), Adoptive Cellular Immunotherapy of Cancer. Marcel Dekker, Inc. New York, pp. 191-206, 1989.
296. Oldham, R.K.: Biological response modifiers. In Kaiser, H.E. (Ed.) Progressive Stages of Malignant Neoplastic Growth. Martinus Nijhoff, pp. 1-8, 1989.
297. Friedman, R.M., Oldham, R.K.: Antitumor effects of interferons. In Kaiser, H.E. (Ed.) Progressive Stages of Malignant Neoplastic Growth. Martinus Nijhoff, 1989.
298. Oldham, R.K., Maleckar, J.R., Friddell, C.S., Lewko, W.M., West, W.H., Yannelli, J.R.: Tumor-derived activated cells: preliminary laboratory and clinical results. Clinical Chemistry, 35(8): 1989.
299. Lewko, W.M., Nayak, S.N., Hubbard, W.J., Thurman, G.B., Oldham, R.K.: Chemosensitivity testing in a tumor acquisition, propagation, and preservation program. Mol. Biother. 1(5): 256- 260, 1989.
300. Oldham, R.K.: Why deny health care? In: The Individualist. South Africa, 14(4):7-8, 1989.
301. Maleckar, J.R., Friddell, C.S., Sferruzza, A., Thurman, G.B., Lewko, W.M., West, W.H., Oldham, R.K., Yannelli, J.R.: Activation and expansion of tumor-derived activated cells for therapeutic use. J. Nat'l Cancer Inst., 1(21):1655-1660, 1989.
302. West, W.H., Tauer, K.W., Yannelli, J.R., Marshall, G.D., Orr, D.W., Lewis, M., Birch, R., Oldham, R.K.: Multiple cycles of constant infusion recombinant interleukin-2 in adoptive cellular therapy of metastatic renal carcinoma. Mol. Biother. 1(5): 268-274, 1989.
303. Gazitt, Y., He, Y.H., Chang, L., Gangavalli, A., Hubbard, W.J., Oldham, R.K.: Establishment and characterization of a malignant lymphoid cell line from chronic lymphocytic leukemia patient. Mol. Biother. 1(6):328-333, 1989.
304. Oldham, R.K.: Clinical research in cancer: a time for consensus. Mol. Biother. 1(5):242-243, 1989.
305. Lewko, W.M., Ladd, P.A., Pridgen, D., He, Y-J, Vaghmar, R., Husseini, S., Chang, L., Moore, M., Thurman, G.B., Oldham, R.K.: Tumor acquisition propagation and preservation: culture of human colorectal cancer. Cancer, 64:1600-1608, 1989.
306. Oldham, R.K., Lewis, M., Orr, D.W., Liao, S.K., Ogden, J.R., Hubbard, W.H., Birch, R.: Individually specified drug immunoconjugates in cancer treatment. R.L. Ceriani (Ed.) In: Breast Cancer Immunodiagnosis and Immunotherapy. Plenum Publishing. PP. 219-230, 1990.

307. Oldham, R.K., Lewis, M., Orr, D.W., Liao, S.K., Ogden, J.R., Hubbard, W.H., Birch, R.: Individually specified drug immunoconjugates in cancer treatment. Imperial Cancer Research Conference. England, Intl. J. Biol. Markers, 4(2):65-77, 1989.
308. Oldham, R.K.: Cancer cures: by the people, for the people, at what cost? Mol. Biother. 2(1):2-3, 1990.
309. Horton, S.A., Oldham, R.K., Yannelli, J.R.: Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res. 50:1686-1692, 1990.
310. Liao, S.K., Flahart, R.E., Kimbro, B., Horton, L., Oldham, R.K., Hilgers, J. and Gaag, R.V.D.: Human tumor and normal tissue reactivity of the anti-breast cancer monoclonal antibody BA-Br-3 and its similarity to the anti-epithelial membrane antigen monoclonal antibody E29. Cancer Immunol. Immunother. 31:65-75, 1990.
311. Yannelli, J.R., Crumpacker, D.B., Good, R.W., Friddell, C.D., Poston, R., Horton, S., Maleckar, J.R., Oldham, R.K.: Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy. J. Immunol. Methods. pp. 10-20, Feb., 1990.
312. Oldham, R.K.: Research funding: a disclosure item. Mol. Biother. 2(2):66, 1990.
313. Oldham, R.K.: Contrast Medium "Recalls" Interleukin-2 Toxicity. "Letter to the Editor", J. Clin. Onc. 8(5): 942-943, 1990.
314. Dillman, R.O., Oldham, R.K., Barth, N.M.: Recombinant Interleukin-2 and Adoptive Immunotherapy Alternated with Dacarbazine therapy in melanoma: A National Biotherapy Study Group Trial. J. Nat'l Cancer Inst. 82(16): 1345-1349, 1990.
315. Oldham, R.K.: PVB chemotherapy: cost benefit analysis. "Letter to the Editor" J. Nat'l Cancer Inst. 82(8):714, 1990.
316. Oldham, R.K.: Why deny health care? Clear Thinking. 38:2-3, 1990.
317. Avent, R.A., Birch, R., Oldham, R.K.: Successful clinical trials in the private sector: the NBSG experience. Advances in Cancer Control. 339:419-423, 1990.
318. Liao, S.K., Horton, L., Flahart, R., Oldham, R.K.: Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas. Human Antibody Hybridomas. 1(2), 66-76, 1990.
319. Oldham, R.K.: Cancer and diabetes: are there similarities? Mol. Biotherapy. 2(3): 130-131, 1990.
320. Oldham, R.K.: Letter to the Editor: Selling Experimental Treatment. Hastings Center Report. 20(6):43-44, 1990.
321. Oldham, R.K., Maleckar, J.R., West, W.H., Yannelli, J.R.: IL-2 and cellular therapy: LAK and TDAC. IN: Cytokines in Hemapoiesis, Oncology and AIDS. (Eds): Freund, et al. Springer- Verlag, Berlin. PP. 661-671, 1990.
322. Oldham, R.K.: Natural Killer cells: history, relevance, and clinical applications. Natural Immunity and Cell Growth Regulation. 9:297-312, 1990.
323. Yannelli, J.R., Maleckar, J.R., West, W.H., Oldham, R.K.: Cellular biotherapy of cancer: generation, characterization and use of anti-tumor effector cells. IN: The Biology and clinical application of Interleukin-2. (Ed): Rees, R., Oxford University Press, London. PP. 120-138, 1990.
324. Oldham, R.K.: Set my factors free. Molecular Biotherapy. 2(4):194-195, 1990.

325. Oldham, R.K.: Monoclonal antibody-drug immunoconjugates and the individualization of cancer biotherapy. IN: Proceedings of the 12th World Congress of Obstetrics and Gynecology. (Ed): Fawcett C., Parthenon Publishing, Lancaster, 1989.
326. Oldham, R.K.: Whose rights come first? *Molecular Biotherapy*. 3(2):58-59, 1991.
327. Avner, B., Swindell, L., Sharp, E., Liao, S.K., Ogden, J.R., Avner, B.P., Oldham, R.K.: Evaluation and clinical relevance of patient immune responses to intravenous therapy with murine monoclonal antibodies conjugated to Adriamycin. *Molecular Biotherapy*. 3(1):14-21, 1991.
328. Lewko, W.M., Vaghmar, R., Hubbard, D., Moore, M.S., He, Y.J., Change, L., Husseini, S., Wallwork, K., Thurman, G.B., Oldham, R.K.: Cultured cell lines from human breast cancer biopsies and xenografts. *Breast Cancer Research and Treatment*. 17:121-129, 1990.
329. Lewko, W.M., Vaghmar, R., Maleckar, J.R., Husseini, S., Montgomery, C.A., Thurman, G.B., Oldham, R.K.: Cultured breast cystosarcoma phylloides cells and applications to patient therapy. *Breast Cancer Research and Treatment*. 17:131-138, 1990.
330. Oldham, R.K.: Cancer research: a public trust. *BioPharm*. 4(3):8-9, 1991.
331. Oldham, R.K.: Is informed consent a function of who pays? *Molecular Biotherapy*. 3(1):2-5, 1991.
332. Oldham, R.K., Stark, J., Barth, N.M., Hoogstraten, B., Brown, C.H., O'Connor, T., Dupere, S., Birch, R.: Continuous infusion interleukin-2 and cyclophosphamide as treatment of advanced cancer: An NBSG trial. *Molecular Biotherapy*. 3(2):74-78, 1991.
333. Oldham, R.K., Dillman, R.O., Yannelli, J.R., Barth, N.M., Maleckar, J.R., Sferruzza, A., Cohen, R.J., Minor, D.R., Spittler, L., Birch, R., West, W.H.: Continuous infusion interleukin-2 and tumor derived activated cells as treatment of advanced solid tumors: An NBSG Trial. *Molecular Biotherapy*. 3(2):68-73, 1991.
334. Oldham, R.K.: The rights and wrongs of national health care. *Pharmaceutical Executive*. 11(4):92-93, 1991.
335. Oldham, R.K.: Letter to the editor: Reimbursement for clinical investigation. *The Pharos*. 54(2):33, 1991.
336. Oldham, R.K.: Our Drug-Pricing Policies Ignore the Consumer. *The Medical Herald*. 1(10):13, 1991.
337. Oldham, R.K.: FDA Places Patient Behind Process. *The Review Appeal*, August 21, 1991.
338. Oldham, R.K., Thurman, G.B.: Effects of cytokines on recovery from radiation exposure. IN: *Medical Radiology - Diagnostic Imaging and Radiation Oncology*. Volume "Concomitant Continuous Infusion Chemotherapy and Radiation". (Eds.): Rotman, M., Rosenthal, C.J., Springer-Verlag, New York, pp. 105-110, 1991.
339. Oldham, R.K.: Cancer biotherapy: general principles. IN: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy* (2nd Edition) Marcel Dekker, New York, pp. 1-22, 1991. 1990.
340. Oldham, R.K.: Developmental therapeutics and the design of clinical trials. IN: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy* (2nd Edition). Marcel Dekker, New York, pp. 55-72, 1991.
341. Smalley, R.V., Oldham, R.K.: Chemical inducers of lymphokines. IN: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy* (2nd Edition). Marcel Dekker, New York, pp. 299-326, 1991.
342. Oldham, R.K.: Drug immunoconjugates. IN: Oldham, R.K. (Ed.) *Principles of Cancer Biotherapy* (2nd Edition). Marcel Dekker, New York, pp. 457-470, 1991.
343. Oldham, R.K.: Biotherapy in autologous bone marrow transplantation. IN: Oldham, R.K. (Ed.) *Principles of*

- Cancer Biotherapy (2nd Edition). Marcel Dekker, New York, pp. 493-502, 1991.
344. Orr, D.W., Oldham, R.K.: Cancer biotherapy: 1990 Disease related activity. In: Oldham, R.K. (Ed.) Principles of Cancer Biotherapy (2nd Edition). Marcel Dekker, New York, pp. 637- 665, 1991.
345. Oldham, R.K.: Speculations for the 1990's. In: Oldham, R.K. (Ed.) Principles of Cancer Biotherapy (2nd Edition). Marcel Dekker, New York, pp. 667-674, 1991.
346. Dillman, R.O., Oldham, R.K., Barth, N.M., Cohen, R.J., Minor, D.R., Birch, R., Yannelli, J.R., Maleckar, J.R., Sferruzza, A., Arnold, J.A., West, W.H.: Continuous interleukin-2 and tumor infiltrating lymphocytes as treatment of advanced melanoma. *Cancer*. 68(1):1-8, 1991.
347. Oldham, R.K.: Custom tailored drug immunoconjugates in cancer therapy. *Molecular Biotherapy*. 3(3):148-162, 1991.
348. Oldham, R.K.: Cancer research for whom? *Bio/Technology*. 9:772, 1991.
349. Dillman, R.O., Oldham, R.K., Tauer, K.W., Orr, D.W., Barth, N.M., Blumenschein, G., Arnold, J., Birch, R., West, W.H.: Continuous Interleukin-2 and Lymphokine Activated Killer Cells for Advanced Cancer: An NBSG Trial. *Journal of Clinical Oncology*. 9:1233-1240, 1991.
350. Oldham, R.K.: In Cancer Research, Put the Patient First. *Wall Street Journal*, August 7, 1991.
351. Oldham, R.K.: Cancer research: A public trust. *Molecular Biotherapy*. 3(3):122-124, 1991. 1991.
352. Oldham, R.K.: Billing for physicians in training: educational subsidy or fraud? *The Pharos*. 54(4):19-20, 1991.
353. Oldham, R.K.: Letter to the editor: Practice-based research. *Journal of the Southern Medical Association*. 84(11):1414, 1991.
354. Oldham, R.K.: Peer Review. *Molecular Biotherapy*. 4:2-3, 1992.
355. Reiker, P.P., Clark, E.J., Fogelberg, P.R., Oldham, R.K.: Perceptions of quality of life and quality of care for cancer patients receiving biological therapy. *Oncol. Nursing Forum*. 19(3):433-440, 1992.
356. Oldham, R.K., Blumenschein, G., Schwartzberg, L., Birch, R., Arnold, J.: Combination biotherapy utilizing interleukin-2 and alpha-interferon in patients with advanced cancer: An NBSG Trial. *Molecular Biotherapy*. 4:4-9, 1992.
357. Oldham, R.K.: IL-2 based therapy: role of LAK and TDAC cells, interferon and other cytokines in successful therapy. IN: *Frontiers of Mucosal Immunology*, Volume 2. (Eds.): Tsuchiya, Nagura, HibiMoro. Elsevier Science Publications, Amsterdam, pp. 481-484, 1991.
358. Oldham, R.K.: Gene Therapy and Cancer: Is It for Everyone. *Cancer Investigation* 10(6):607-609, 1992.
359. Oldham, R.K.: Innovations in Science. *Molecular Biotherapy*. (4):164-165, 1992.
360. Oldham, R.K.: Biological approaches to cancer therapy. Presentation of the First Italian-American Symposium on Immuno Biologic Aspects in Oncology, New York City, September, 1992.
361. Oldham, R.K.: Therapy with Tumor Derived Activated Lymphocytes. In: *Tumor Immunology*. (Ed): Goldfarb, R. and Whiteside, T. Marcell Dekker Publishing, New York, pp. 251-271, 1992.
362. Dillman, R., Church, C. Oldham, R.K., West, W. W., Swartzberg, and L., Birch: Inpatient Continuous Infusion Interleukin-2 in 788 Cancer Patients: The NBSG Experience. *Cancer* 71:2358-2370, 1993.
363. Oldham, R.K.: Cancer Biotherapy: 1993 to the Millenium and More! *Cancer Biotherapy*. 8(1):1-2, 1993.



364. Oldham, R.K.: Fundamentally Flawed. *Cancer Biotherapy* 8(2): 111-114, 1993.
365. Oldham, R.K.: What's the Score? *Cancer Biotherapy* 8(3): 187-188, 1993.
366. Oldham, R.K.: Why Deny Health Care? In: Politicized Medicine, The the Freeman Classics, The Foundation for Economic Education, Inc. Irvington-on-Hudson, New York, pp. 139-141. 1993.
367. Oldham, R.K.: Disclosure in Research Funding. *Cancer Biotherapy* 8(4): 273-274, 1993.
368. Oldham, R.K.: Cancer Research: Does it Deliver for the Patient? *Cancer Biotherapy* 9(1): 99-102, 1994.
369. Oldham, R.K.: Cancer Biotherapy: The First Year. *Cancer Biotherapy* 9(3): 179-181, 1994.
370. Oldham, R.K., Lewko, W., Good, R., Bowman, D., Smith, T.: Growth of Tumor Derived Activated T-Cells for the Treatment of Cancer. *Cancer Biotherapy* 9(3): 211-224, 1994.
371. Cancer Biotherapy with Interferon, Interleukin-2 and Tumor-Derived Activated Cells (TDAC). R.K. Oldham, W. Lewko, Ph.D., R. Good and E. Sharp, RN, Biological Therapy Institute, Franklin, TN, Cancer Therapeutics, Inc., Franklin, TN and Williamson Medical Center, Franklin, TN. *IN VIVO* (Special Issue 3) On behalf of the International Society for the study of Comparative Oncology. 1994.
372. Oldham, R.K.: The War on Cancer: New Battle Plan Needed. *Cancer Biotherapy* 9(4): 289-290, 1994.
373. Lewko, W.M., Smith, T.L., Bowman, D.J., Good, R.W., Oldham, R.K.: Interleukin-15 and the Growth of Tumor Derived Activated T-Cells. *Cancer Biotherapy* 10(1): 13-20, 1995.
374. Oldham, R.K., Cancer Biotherapy: The Field Matures. *Cancer Biotherapy* 10(2): 91-93, 1995.
- 374A. Oldham, R.K., Cancer Biotherapy: Biotherapy and Radiopharmaceuticals 10(4):251-252, 1995.
375. Dillman, R., Wiemann, M., Oldham, R.K., Soori, G., Bury, M., Hafer, R., Church, C., DePriest, C.: Interferon  $\gamma$ -2a and External Beam Radiotherapy in the Initial Management of Patients with Glioma: A Pilot Study of the National Biotherapy Study Group. *Cancer Biotherapy* 10(4): 265-271, 1995.
376. Oldham, R.K., FDA Update: 1996. *Cancer Biotherapy & Radiopharmaceuticals* 11(1): 1-2, 1996.
377. Oldham, R.K., Magic Bullets: "Deja vu all over again." *Cancer Biotherapy & Radiopharmaceuticals* 11(2): 97-98, 1996.
378. Oldham, R.K., Government Oversight or What. *Cancer Biotherapy & Radiopharmaceuticals* 11(3): 165-166, 1996.
379. Oldham, R.K., FDA Reform-Real or Just More Politics? *Cancer Biotherapy & Radiopharmaceuticals* 11(4): 227-228, 1996.
380. Oldham, R.K., Progress in the Monoclonal Antibody Therapy of Cancer. *Cancer Biotherapy & Radiopharmaceuticals* 11(5): 279, 1996.
381. Soori, G.S., Peterson, C., Oldham, R.K., Cogburn, B.E., Honeycutt, P.J., Qan, W.D.Y., Dobbs, T.W., National Biotherapy Study Group: Chemo-Biotherapy with Chlorambucil and Alpha-Interferon in Patients with non-Hodgkin's Lymphoma - A NBSG Phase II Study. Abstract, SBT, October, 1996.
382. Oldham, R.K., Innovation in Science. *Cancer Biotherapy & Radiopharmaceuticals* 11(6): 345-346, 1996.
383. Oldham, R.K., Cancer and Diabetes: Are There Similarities? *Cancer Biotherapy & Radiopharmaceuticals*

- 12(1): 1-3, 1997.
384. Oldham, R.K., Peer Review. *Cancer Biotherapy & Radiopharmaceuticals* 12(2): 63-64, 1997.
385. Oldham, R.K., Regulatory Hierarchies. *Cancer Biotherapy & Radiopharmaceuticals* 12(3): 137-140, 1997.
386. Oldham, R.K., Cancer Biotherapy: General Principles. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K. (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
387. Oldham, R.K., Developmental Therapeutics and the Design of Clinical Trials. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K. (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
388. Schulof, R., Oldham, R.K., Current Concepts in Immunology. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K., (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
389. Lewko, W., Smalley, R.V., Oldham, R.K., Lymphokines and Cytokines. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K., (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
390. Oldham, R.K., Foon, K.A., Drug Immunoconjugates. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K., (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
391. Oldham, R.K., Biotherapy in Autologous Bone Marrow Transplantation. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K., (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
392. Oldham, R.K., Growth and Maturation Factors in Leukemia. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K., (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
393. Oldham, R.K., Marshall, E., Cancer Biotherapy: 1990 Disease-Related Activity. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K., (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
394. Oldham, R.K., Speculations for the 1990's. *In Principles of Cancer Biotherapy (Third Edition)*. Oldham, R.K. (Ed.): Kluwer Academic Publishers, The Netherlands, 1997.
395. Dillman, R.O., Crispin, R., Oldham, R.K.: The Cancer Biotherapy Research Group (CBRG), formerly the National Biotherapy Study Group (NBSG): a 10-Year Perspective. *Cancer Biotherapy & Radiopharmaceuticals* 12(4), 229-242,1997.
396. Dillman, R.O., Church C., Barth, N.M., Oldham, R.K., Wiemann, M.C.: Long-term Survival after Continuous Infusion Interleukin-2. *Cancer Biotherapy & Radiopharmaceuticals* 12(4):243-250, 1997.
397. Oldham, R.K.: Cancer Biotherapy: When, Why and How Long? *Cancer Biotherapy & Radiopharmaceuticals* 12(5):295-296, 1997.
398. Oldham, R.K.: Interleukin-2: Dose, Schedule and Route. *Cancer Biotherapy & Radiopharmaceuticals* 12(6):363-365, 1997.
399. Oldham, R.K., Reid, W.K., Adler, S., Preisler, H.D., Reilly, M.B., and Barnett, D. A Phase I and Pharmacokinetic Study of CBT-1 as a Multidrug Resistance Modulator in the Treatment of Patients with Advanced Cancer. *Cancer Biotherapy & Radiopharmaceuticals* 13(2):71-80, 1998.
400. Oldham, R.K.: Editorial. *Cancer Biotherapy & Radiopharmaceuticals* 13(3):141-142, 1998.
401. Oldham, R.K.: Editorial. *Cancer Biotherapy & Radiopharmaceuticals* 13(4):211, 1998.
402. Oldham R.K. and DeNardo, G.L. Editorial, "Historical Vignettes" *Cancer Biotherapy & Radiopharmaceuticals* 14(2):65-66, 1999.

403. Soori, G.S., Oldham, R.K., Dobbs, T.W., Bury, M.J., Church, C.K., DePriest, C: Chemo-Biotherapy with 5-Fluorouracil, Leucovorin, and Alpha Interferon in Metastatic Carcinoma of the Colon - A Cancer Biotherapy Research Group [CBRG] Phase II Study. *Cancer Biotherapy & Radiopharmaceuticals* 15(2):175-184, 2000.
404. Oldham, R.K. Fundamentally Different. *Cancer Biotherapy & Radiopharmaceuticals* 14(6):413-415, 1999.
405. Oldham, R.K. Editorial: Treatment of Drug Resistance: Biotherapy or Chemotherapy? *Cancer Biotherapy & Radiopharmaceuticals* 13(2):69-70, 1998.
406. Oldham, R.K., Reid, W.K., and Barnett, D. Phase I Study of CBT-1 and Taxol in Patients with Taxol Resistant Cancers. *Cancer Biotherapy & Radiopharmaceuticals* 15(2):153-160, 2000.
407. Lewko, Walter M., Hall, Peggy B., and Oldham, R.K. Growth of Tumor-Derived Activated T Cells for the Treatment of Advanced Cancer. *Cancer Biotherapy & Radiopharmaceuticals*. 15(4):357-366, 2000.
408. DeNardo, G.L. and Oldham, R.K. Editorial: Banner Millennium 2000 Year for CB&R and Mary Ann Liebert Cancer Biotherapy and Radiopharmaceuticals 15 (6): 527-528, 2000
409. Oldham R.K. Cracking the FDA Code Wall Street Journal Op/Ed 2/2/01
410. Oldham R.K. Capital will be the driving force of biotechnology Augusta Chronicle Op/Ed 11/29/00
411. Oldham R.K. Lengthy FDA approval process can be deadly quagmire for cancer patients Augusta Chronicle Op/Ed 2/24/01
412. Oldham R.K. Why We Need to Rethink the Regs. *Genome Technology* Op/Ed August 2001
413. DeNardo G.L. and Oldham R.K. Editorial: Year 2001: An Even Better Year for CB&R. *Cancer Biotherapy and Radiopharmaceuticals* 16 (6) :449-450 2001
414. Oldham R.K. Our Bodies, Our Cells? Wall Street Journal Op/Ed 6/4/01
415. Oldham R. K. Stem Cells: Private Sector Can Do It Better Wall Street Journal Op/Ed 8/28/01
416. Oldham R.K. Informed Opinions: Editorial Introduction *Cancer Biotherapy and Radiopharmaceuticals* 17(3) 247 2002
417. DeNardo G.L. and Oldham R.K. Editorial: Year 2002: The Best Year Yet for CB&R. *Cancer Biotherapy and Radiopharmaceuticals* 17(6) 599-600 2002
418. Oldham R.K. FDA Trials Cost Lives Wall Street Journal Op/Ed 3/3/02
419. Oldham R.K. and Dillman R.O. Editorial: Gold Standard or Wrong Standard? *Cancer Biotherapy and Radiopharmaceuticals*, 19(3) 271-272, 2004
420. Oldham R.K. Unlucky Jim Wall Street Journal Op/Ed 2/16/05
421. DeNardo G.L. O'Donnell R.T. Oldham R.K. and DeNardo S.J. A Revolution in the Treatment of Non-Hodgkin's Lymphoma. *Cancer Biotherapy and Radiopharmaceuticals* 13(4):P213-223, 1998
422. Robey R.W. Shukla S. Finley E.M. Oldham R.K. Barnett D. Ambedkar S.V. Fojo T. and Bates S.E. Inhibition of P-glycoprotein (ABCC)-mediated transport by the orally administered inhibitor, CBT-1 *Biochem Pharm* 75:1302-1312, 2008

423. DeNardo G.L. and Oldham R.K. 2008: State of Affairs for CB&R. *Cancer Biotherapy and Radiopharmaceuticals* 23(1):1-2, 2008
424. Oldham R.K. and Dillman R.O. Monoclonal Antibodies in Cancer Therapy: Twenty-Five Years of Progress. *JCO* 26(11):1774-1777.
425. Cancer Biotherapy: General Principles  
*Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
426. Developmental Therapeutics and Genomics In Cancer Therapy  
*Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
427. Current Concepts In Immunology  
*Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
428. Therapeutic Approaches to Cancer-associated Immune Suppression  
*Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
429. Cytokines  
*Walter M. Lewko and Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
430. Drug Immunoconjugates  
*Malek Safa, Kenneth A. Foon, and Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
431. Stem Cell/Bone Marrow Transplantation as Biotherapy  
*Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
432. Growth and Differentiation Factors as Cancer Therapeutics  
*Kapil Mehta, Robert K. Oldham, and Bulent Ozpolat*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
433. Cancer Biotherapy: 2009 Disease-related Activity  
*Robert K. Oldham and Robert O. Dillman*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
434. Speculations for 2009 and Beyond  
*Robert K. Oldham*, Principles of Cancer Biotherapy, 5<sup>th</sup> Edition, Springer 2009
435. Monoclonal Antibody Therapy of Solid Malignancies pp 217-267  
*Robert O. Dillman and Robert K. Oldham*  
Immunoglobulin Therapy Eds: A.H. Lazarus and J.W. Semple  
AABB Press 2010

## BOOKS

1. Weiner, R.S., Oldham, R.K. and Schwarzenberg, L.: Cryopreservation of Normal and Neoplastic Cells. Inserm, France, 1973.
2. Mathe, G. and Oldham R.K.: Complications of Cancer Chemotherapy Recent Results in Cancer Research, Vol. 49. New York, Springer- Verlag, 1974.
3. Mathe, G. and Oldham, R.K.: Bone Marrow Transplantation, Current Results and Prospects. Vol. 6, Transplantation Proceedings, 1974.
4. Greco, F.A., Oldham, R.K. and Bunn, P.A.: Small Cell Lung Cancer. New York, Grune and Stratton, 1981.
5. Fer, M.F., Greco, F.A. and Oldham, R.K.: Poorly Differentiated Neoplasms and Tumors of Unknown Origin, Seminars in Oncology. New York, Grune and Stratton, 1982.
6. Finter, N.B. and Oldham, R.K.: Interferon: In Vivo and Clinical Studies. Volume 4, Elsevier Biomedical Press. Netherlands, 1985.
7. Talmadge, J.E., Fidler, I.J., and Oldham, R.K.: Screening for Biological Response Modifiers: Methods and Rationale. Martinus Nijhoff, Boston, 1985.
8. Fer, M.F., Greco, F.A., Oldham, R.K. (Eds.) : Poorly Differentiated Neoplasms and Tumors of Unknown Origin. Grune and Stratton, New York, 1986.
9. Oldham, R.K.: Principles of Cancer Biotherapy. Raven Press, New York, 1987.
10. Oldham, R.K.: Principles of Cancer Biotherapy (Second Edition). Marcel Dekker, New York, 1991.
11. Oldham, R.K.: The Cure. Pulse Publications, Franklin, TN, 1991.
12. Oldham, R.K.: BioEthics: Opportunities, Risks and Ethics: The Privatization of Cancer Research. Media America, Franklin, TN, 1992.
13. Oldham, R.K.: Principles of Cancer Biotherapy (Third Edition). Kluwer Academic Publishers, The Netherlands, 1998.
14. Oldham, R.K.: Principles of Cancer Biotherapy (Fourth Edition). Kluwer Academic Publishers. The Netherlands, 2004
15. Oldham, R.K. The Resurrection Harbor House Books, 2004
16. Oldham, R.K. and Dillman, R.O.: Principles of Cancer Biotherapy (Fifth Edition). Springer Netherlands, 2009